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ABSTRACT: 
 
Bcl-2, an anti-apoptotic member of the Bcl-2 family of proteins, plays a major 
role in apoptosis regulation at the level of endoplasmic reticulum (ER) by controlling 
luminal Ca2+ concentration of ER through different mechanisms. It has been reported 
by Dremina et al. that Bcl-2 can directly interact with Sarcoplasmic/Endoplasmic 
Reticulum Calcium ATPase (SERCA), the Ca2+ pump in SR/ER membrane which 
transports Ca2+ from cytoplasm to the lumen of SR/ER, causing inactivation and also 
translocation of SERCA from Caveolae-Related Domains (CRD) of the SR/ER 
membrane.  
The work reported here are the important characteristics of the SERCA/Bcl-2 
interactions using wild type and three mutants, G145E, S24C/C158S and 
S205C/C158S, of the C-terminal truncated protein, Bcl-2Δ21. Photo and chemical 
cross-linking of the interacting proteins, Ca2+-ATPase activity assay of SERCA, 
Sucrose Density Gradient (SDG) fractionation of the SR membrane, 
immunoprecipitation and the fusion protein GST-Bcl-2Δ21 (GST stands for 
Glutathione-S-Transferase) binding assay are the approaches used to examine the 
interaction. Based on the cross-linking studies the two proteins can interact with both 
1:1 and 2:1 (Bcl-2Δ21: SERCA) molar ratios. The distance between the 
interface/interfaces of the Bcl-2Δ21/SERCA complex can range from ~6-14Å. BH1 
and BH2 domains (BH stands for Bcl-2 Homology domains which are the conserved 
domains found in the Bcl-2 family), hence the hydrophobic surface groove of Bcl-
2Δ21 is identified as directly involved in the interactions with SERCA whereas the 
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BH4 domain of Bcl-2Δ21 does not belong to the interface of the Bcl-2Δ21/SERCA 
complex. Based on mass spectrometric findings, the BH1 domain of Bcl-2Δ21 
interacts with the ATP binding domain of SERCA.  
According to the immunoprecipitation and GST-Bcl-2Δ21 binding assay 
experiments all the three mutants, S24C/C158S, S205C/C158S and G145E of Bcl-
2Δ21 studied can directly associate with SERCA. However, the G145E mutant is a 
loss-of-function whereas the two Cys-mutants, S24C/C158S and S205C/C158S, are 
gain-of-function on SERCA inactivation and translocation, as revealed by Ca2+-
ATPase activity assay and Sucrose Density Gradient (SDG) fractionation 
experiments. Therefore the conserved residue G145 is a critical hot spot for the Bcl-
2Δ21-mediated inactivation and translocation of SERCA. 
Mitsugumin-29 (Mg29) is a recently found protein expressed in the triad-
junction complex which connects the cell surface to the SR membrane of skeletal 
muscle. Some evidence on the involvement of Mg29 in this Bcl-2Δ21/SERCA 
interaction and also on the effect of aging in Bcl-2Δ21/SERCA association is reported 
here. These findings support Bcl-2/SERCA interactions as a possible mechanism of 
apoptosis control by Bcl-2 through regulation of Ca2+ homeostasis at the ER. 
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Chapter 1:  
Introduction, Significance and Objectives. 
 
1.1: Apoptosis, Bcl-2 family and Bcl-2. 
Apoptosis or programmed cell death is an evolutionarily conserved biological 
process. Proper apoptosis machinery is vital in physiological processes such as fetal 
development, tissue homeostasis and also in cellular defense mechanisms against 
pathologies (1-7). Impaired apoptosis regulation contributes to numerous diseases 
including cancer, stroke, heart failure, AIDS, neurodegenerative disorders and auto 
immune diseases (1-9). Molecular mechanisms involved in this programmed cell 
death machinery are well characterized to date and investigation of underlying 
mechanisms is important to discover therapeutics to cure diseases associated with 
altered apoptosis. 
There are two well known pathways, intrinsic and extrinsic, for apoptosis. The 
intrinsic pathway is triggered by intracellularly originated death stimuli whereas in 
the extrinsic pathway the death stimulus is extracellular. Both these pathways direct 
the apoptotic cell to undergo number of morphological and biochemical changes. 
Caspases, a family of intracellular proteases, are directly or indirectly responsible for 
all these changes. Caspase activation is directly or indirectly regulated by other 
apoptosis associated intracellular proteins, which act by either activating or inhibiting 
caspases (1-7). Participation of mitochondria in caspase activation in the intrinsic 
apoptosis pathway is well characterized (1-7, 10, 11). Endoplasmic reticulum (ER) 
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stress-induced caspase activation and also caspase-independent apoptosis are two 
other newly emerging apoptosis mechanisms (7).  
Among the various modulators of apoptosis, Bcl-2 family members are well 
known for their involvement in the mitochondrially-initiated intrinsic apoptosis 
pathway (10-19). The Bcl-2 family is conserved in metazoans and consists of more 
than two dozens of members (1-7, 10-16). Comparison of primary structures of 
members reveals four conserved amino acid sequence stretches found within the 
family and each member contains at least one of these four homology motifs known 
as Bcl-2 homology domains or BH1, BH2, BH3 and BH4. Functionally, Bcl-2 family 
members are either pro-apoptotic or anti-apoptotic. The balance between pro- and 
anti-apoptotic members in a cell is important in determining the cell fate. Based on 
structural and functional similarities, Bcl-2 family can be divided into three sub 
families; (1) Anti-apoptotic (Pro-survival) members have all four Bcl-2 homology 
domains (eg. Bcl-2, Bcl-xL), (2) Multidomain pro-apoptotic members (Bax family) 
posses BH1, BH2 and BH3 but lacks BH4 (eg.Bax, Bak),   (3) BH3-only pro-
apoptotic members (eg. Bid, Bad) (12-16). Figure 1.1 is a schematic of these three 
Bcl-2 sub families. 
 Anti-apoptotic member Bcl-2 is the founding member of the Bcl-2 family in 
mammals. Since the discovery of Bcl-2, at least 20 Bcl-2 family members have been 
identified in mammals (12). The Bcl-2 gene was found activated by chromosome 
translocation and the protein was found over expressed in human B-cell lymphomas 
(20). Thereafter, over expressed Bcl-2 was identified in many lymphomas and solid 
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tumors and Bcl-2 over expression makes those abnormal cells resistant to chemo- and 
radio-therapy (21, 22). This led researchers to investigate cytoprotective mechanisms 
of Bcl-2.  
 
 
 
FIGURE 1.1: Bcl-2 family proteins: Bcl-2 family can be divided into three sub 
families; (1) Anti-apoptotic (Pro-survival) members have all four Bcl-2 homology 
domains. (2) Multidomain pro-apoptotic members (Bax family) posses BH1, BH2 
and BH3 but lacks BH4.  (3) BH3-only pro-apoptotic members. (Adapted from Cory, 
S., and Adams, J.M. (2002) Nat. Rev. Cancer 2(9), 647-656.) 
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Bcl-2 is an integral membrane protein. It contains nine α helices and a long 
unstructured loop between α1 and α2. The structure of Bcl-2 was first determined 
using a chimeric protein in which a part of unstructured loop of Bcl-2 was replaced 
with a part of Bcl-xL loop. As revealed by this NMR spectroscopic study, Bcl-2 
contains two central hydrophobic α helices, α5 and α6, which are surrounded by five 
other amphipathic helices (23).  Ribbon depiction of the structure of Bcl-2ΔTM, 
transmembrane domain truncated Bcl-2, is shown in figure 2. Important feature of 
this structure is that it has an elongated hydrophobic surface groove formed by α 
helices in conserved motifs BH1, BH2 and BH3 (23,24). The C-terminal hydrophobic 
helix α9 forms the transmembrane (TM) domain which helps the molecule to anchor 
to membranes (24-26). The two central hydrophobic helices, α5 and α6, are also 
reported to have membrane insertion properties (27). Figure 3 is a cartoon of Bcl-2 
indicating different regions and known functions/importance associated with those 
regions.  
Bcl-2 is a multifunctional protein which can insert its cytoprotective action 
through numerous mechanisms. Some of these mechanisms are well established 
whereas others are poorly understood or not identified yet. Bcl-2 localizes and plays 
its cell protective role in different subcellular compartments such as the 
mitochondrial, endoplasmic reticulum (ER) and nuclear membrane (28-30). Role of 
Bcl-2 at the level of mitochondria is well known (10-18) where as its role at the level 
of the ER is poorly understood and currently under investigation (31-58). Currently 
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known information about the Bcl-2’s anti apoptotic activity in the ER will be 
discussed in detail in section 1.3 of this chapter.  
 
 
FIGURE 1.2: Ribbon depiction of the structure of Bcl-2: Structure of Bcl-2 was 
first determined using a truncated Bcl-2/Bcl-xL chimeric protein in which a part of the 
unstructured loop of Bcl-2 was replaced with a part of Bcl-xL loop and the C-terminal 
21 amino acids were truncated (23). (Modified from Petros, A.M., Olejniczak, E.T., 
and Fesik, S.W. (2004) Biochim. Biophys. Acta. 1644(2-3), 83-94.) 
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FIGURE 1.3: Topology of Bcl-2: Different helices, domains and associated 
functions/importance of different regions are indicated. The BH4 domain is known to 
participate in binding with Raf-1 and Calcineurin, two well known binding partners 
of Bcl-2. Important phosphorylation sites which regulate activity of Bcl-2 are located 
in unstructured loop region. The BH3 domain helps in homodimerization and also in 
hetero dimerization with other Bcl-2 family members. The BH1, BH2 and BH3 
domains collectively form the hydrophobic surface groove which acts as the receptor 
domain for dimerization. Membrane anchoring TM domain includes helices 8 and 9.  
(Adapted from Reed, J.C. (1997) Nature 387(6635), 773-776.) 
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Bcl-2 protects mitochondrial membrane integrity while residing on the 
membrane. Pro-apoptotic BH3-only members can heterodimerize with Bcl-2 and 
neutralize it by binding to the hydrophobic surface groove of Bcl-2. This leads other 
pro-apoptotic multi-domain members such as Bax and Bak to homodimerize and 
form channels on the mitochondrial membrane, disturbing the membrane integrity 
and releasing cytochrome-c, which in turn activates caspases (10-19, 25, 26, 28). 
Heterodimerization of Bcl-2 with Bax and Bak is also suggested as an explanation for 
protected mitochondrial membrane integrity by Bcl-2 (59-63). However, a direct 
physical interaction was not revealed by cross-linking (64). Bcl-2 is also reported to 
inhibit opening of permeability transition pore (PTP) in the inner mitochondrial 
membrane (IMM) preventing cyt-c release through those channels (10, 11, 14, 15, 17, 
65). 
Ability to form ion channels in membranes is another fascinating feature of 
Bcl-2 in apoptosis regulation (11, 15, 49, 66-68). Bcl-xL, a structural homolog of Bcl-
2, shows structural similarity to pore forming domains of bacterial toxins such as 
diphtheria toxin (69). This suggests that Bcl-xL / Bcl-2 might form ion channels in 
membranes regulating ion exchange. In fact they are reported to form ion channels in 
synthetic membranes in vitro (11, 70). Phosphorylation/dephosphorylation status of 
Bcl-2 is also important in apoptosis regulation. Several serine and threonine residues 
located in unstructured loop region of Bcl-2 have been identified as phosphorylation 
sites which affect activity and conformation of Bcl-2 upon phosphorylation. There are 
reports on altered anti-apoptotic activity due to phosphorylation of Bcl-2 and 
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physiological kinases and phosphatases involved have been identified (15, 71-82). 
Another anti-apoptotic property of Bcl-2 includes its antioxidative function. Cellular 
antioxidant capacity is reported to be elevated in Bcl-2 over expressing cells (10, 73, 
83, 84). Physical and/or functional interactions of Bcl-2 with other non related protein 
partners is another emerging side of Bcl-2 involvement in apoptosis regulation (15, 
35, 50-58, 68, 76).  
Broadened knowledge of apoptosis-suppression by Bcl-2 helps discovery of 
new or more effective approaches to treat pathologies such as cancer (22). In one 
approach, Bcl-2 expression in cancer cells is suppressed using anti-sense 
oligonucleotides and this approach has advanced to Phase III trials (85). Also there 
are several reports of small organic molecules which bind to the hydrophobic groove 
of Bcl-2 mimicking the binding of BH3 peptides to the groove thus inducing cell 
viability (86-89). New pro-apoptotic drug delivery system including a synthetic BH3 
domain peptide was also reported recently (90).   
 
1.2: Ca2+ signaling and SERCA. 
 
 Ca2+ is an essential second messenger throughout the lifespan of the cell. 
Fertilization, proliferation and differentiation, development, learning and memory, 
contraction, secretion, metabolism and apoptosis are among the important cellular 
processes which are controlled by Ca2+ ions. Cellular Ca2+ signaling is a complex 
network of underlying signaling mechanisms that are tissue specific making the 
network more complex. Basically this network consists of internally or externally 
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generated Ca2+–mobilizing signals, ON/OFF mechanisms to control entry and 
removal of Ca2+ ions to and from the cytoplasm, respectively, and  various Ca2+-
sensitive processes which are triggered by Ca2+ changes within the cell. Proper 
control of Ca2+ signaling is of vital importance for healthy life and various receptors, 
ion channels, pumps, exchangers and Ca2+ binding proteins which act as buffers, are 
important participants in controlling Ca2+ signaling (91-93). 
 The endoplasmic reticulum (ER) (sarcoplasmic reticulum (SR) in muscle 
cells) is the cellular Ca2+ storage compartment. ER/SR has the ability to hold Ca2+ 
within the concentration range of 100-1000μM and this [Ca2+]ER/SR is 103-104 times 
higher compared to [Ca2+]C, cytosolic free Ca2+ concentration, which is about 0.1 μM 
(94). ER/SR Ca2+ uptake, storage and release is controlled by three major classes of 
Ca2+-regulatory proteins. Luminal Ca2+-binding proteins such as calsequestrin and 
calreticulin help Ca2+-storage. Ca2+-release channels such as Ryanodine receptor 
(RyR) and Inositol tris phosphate receptor (IP3R)  help Ca2+-release whereas 
sarco/endoplasmic reticulum Ca2+-ATPase (SERCA),  the calcium pump, helps 
uptake of Ca2+(95,96). 
 More than ten isoforms of SERCA have been identified to date which are 
generated by alternative splicing of three separate genes SERCA1, 2 and 3. Fast-
twitch skeletal muscle isoforms, SERCA1a and SERCA1b are found in adult and 
fetal tissue, respectively. Cardiac and slow-twitch skeletal muscle isoform is 
SERCA2a. Both non-muscle tissues and smooth muscles contain SERCA2b. 
SERCA2c and SERCA2d are relatively rare isoforms. SERCA3a, SERCA3b and 
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SERCA3c are found in non muscle cells such as platelets, lymphoid cells and 
endothelial cells while SERCA3d-SERCA3f are detected only at the mRNA level 
(96, 97). Even though these SERCA isoforms show significant similarities in primary 
structure, they have evolved for specialized functions depending on the cellular 
environment (98-102).  
SERCA is a monomeric transmembrane protein of 110 kDa and its a P-type 
Ca2+-ATPase. It hydrolyses ATP and undergoes autophosphorylation of a conserved 
aspartate residue, upon Ca2+ transport. The energy derived from hydrolysis of one 
ATP molecule is used to transport two Ca2+ ions from the cytoplasm to the lumen 
against a concentration gradient across the ER/SR membrane (97, 98). The crystal 
structure of SERCA reveals a transmembrane domain consisting of ten helices (M1-
M10) and a cytosolic head piece of a mixture of α helices and β strands (103,104). 
The cytosolic head piece consists of three main domains: A-domain (actuator or 
anchor domain –residues 1-50 and 131-238), P-domain (phosphorylation domain – 
residues 330-359 and 605-737) and N-domain (nucleotide/ATP binding domain – 
residues 360-604) (96,103). Out of these three domains, the N-domain is the largest 
(~27 kDa) and A-domain is the smallest (~16 kDa) (104).  More than half of the 
molecule belongs to this cytoplasmic head piece while only small loops between TM 
helices are exposed in the luminal side. The four trans membrane helices M4, M5, 
M6 and M8 form the Ca2+ ion transporting channel and coordinating residues of high 
affinity Ca2+ binding sites are also located in these four helices (105-107). The P and 
N domains together form the active site for ATP hydrolysis and Asp351 of the P-
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domain is the site of autophosphorylation (105,106).  Structure of the sarcoplasmic 
reticulum Ca2+-ATPase is shown in Figure 4 (104). 
According to the popular E1/E2 model for explaining the Ca2+ transport 
mechanism, SERCA switches its conformation back and forth between two different 
conformations, the high Ca2+ affinity E1 state and the low Ca2+ affinity E2 state. A 
number of sequential steps complete the transport cycle (105,106,108). The high 
affinity E1 state is achieved by binding of two Ca2+ ions to SERCA. Then, binding of 
ATP to the N-domain, hydrolysis of bound ATP and autophosphorylation of the P-
domain leads to E1-P, the phosphorylated form of the E1 state. Next, ADP is 
dissociated and the conformation changes to E2-P, the phosphorylated form of the E2 
state, resulting in dissociation of bound Ca2+. Finally, hydrolytic cleavage of the 
phosphate group on Asp351 converts the molecule back to E2 state completing the 
cycle. In the E1 state, high affinity Ca2+ binding sites are accessible from the 
cytoplasmic side where as in the E2 state, low affinity Ca2+ binding sites are exposed 
to the lumen. Therefore the conformational switch from E1 to E2 results in Ca2+ 
transport from the cytoplasm to the lumen (105,106,108).  
There are specific amino acid residues that directly contribute to the process 
while some residues help indirectly, by stabilizing directly involved neighboring 
residues. Based on mutational and structural analysis, Thr441, Glu442, Phe487, 
Arg489, Lys492, Lys515, Arg560 and Leu562 have been identified as critical ATP 
binding residues of the N-domain (109-113). Asp351, Thr 625, Lys 684 and Thr 353  
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FIGURE 1.4: Structure of sarcoplasmic reticulum Ca2+-ATPase (SERCA) from 
two different angles: Cylinders and arrows are used to represent α-helices and β-
strands respectively. The N, P and A domains are labeled. The Helices in TM, A and 
P domains are numbered. TNP-AMP, an ATP analog, shows the ATP binding site 
within the N-domain. Phosphorylation site (D351), binding sites for the inhibitors 
phospholamban (PLN) and thapsigargin (TG), major digestion sites for trypsin (T1 
and T2) and proteinase K (PrtK) are marked. (Adapted from Toyoshima, C., 
Nakasako, M., Nomura, H., and Ogawa, H. (2000) Nature 405 (6787), 647-55.) 
 13
of the P-domain bind with phosphate (109). Inter-domain interactions and relative 
positional changes of domains play a vital role in completing the Ca2+ transport cycle.   
Arg560 of the N-domain and Asp627 of the P-domain interact with each other 
facilitating inter-domain interactions between the N and P domains, required for ATP 
binding and autophosphorylation (109). During the E1/E2 conformational transition, 
the A-domain rotates and forms hydrogen bonds with several residues in the N and P 
domains changing the environment around the phosphorylation residue. This in turn 
facilitates hydrolysis of the phosphate group on Asp351. Also these inter-domain 
interactions aid in opening of the luminal gate for Ca2+ ions (106). Several acidic 
residues located in luminal loops between transmembrane helices also participate in 
this Ca2+ transport process (114).  
Various regulators of enzymatic activity of SERCA have been identified to 
date. Phospholamban (PLN) is a well characterized small protein regulator of 
SERCA. It can reversibly inhibit SERCA by reducing the affinity for Ca2+ (115-120). 
Sarcolipin (SLN) is another regulator of SERCA. This small proteolipid increases 
Vmax for Ca2+ transport while reducing apparent Ca2+ affinity for SERCA. (121). Also 
SLN can regulate SERCA by association with PLN (122,123). Insulin Receptor 
Substrate (IRS) proteins, HSP70 and Phosphatidylinositol 3-kinase (PI3-kinase) are 
three other identified proteins which can bind with and/or regulate SERCA (124-126). 
Post translational modifications such as phosphorylation, oxidation and nitration are 
also considered to be involved in regulation of SERCA activity (127-129). Also 
membrane lipids might involve in regulation of SERCA activity (130-132). 
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1.3: ER/MC apoptotic cross-talk and involvement of Bcl-2. 
Mitochondria (MC) and endoplasmic reticulum(ER) interact both physically 
and functionally regulating Ca2+ signaling events within the cell (133-136).   Under 
normal physiological conditions Ca2+ ions are actively pumped into ER by SERCA. 
Stored Ca2+ is released transiently back into the cytoplasm passively by Inositol tris 
phosphate receptor (IP3R) and Rynodine  Receptor (RyR), Ca2+ release channels in 
ER membrane (137). MC sense this released Ca2+ and a significant fraction of it is 
captured using mitochondrial Ca2+ uniporters (mCU) (133,137). Release of this Ca2+ 
to cytoplasm through mitochondrial Na+/Ca2+ exchangers allows recycling of Ca2+ 
back into the ER(137). This Ca2+ recycling process is efficient due to the close 
localization of the two organelles (134,138). Apoptosis is one of the cellular 
processes in which Ca2+ signaling plays a crucial role, especially in the 
mitochondrial-generated intrinsic pathway of apoptosis. Concentration of Ca2+ in ER 
determines the magnitude of Ca2+ signal which enters the MC and higher 
mitochondrial Ca2+ signals can trigger the mitochondrial-generated intrinsic apoptosis 
pathway (1-7, 10, 11, 137). 
Cellular processes that increase [Ca2+]ER level and/or enhance Ca2+ transport 
from ER to MC are apoptogenic. Overexpression of SERCA causes elevated [Ca2+]ER  
leading to cell death (44,137). Bcl-2 family members are known to regulate [Ca2+]ER  
level and/or Ca2+ transfer from the ER to MC (31-35,45-47,137,139-144). There are a 
number of reports in this regard, involving Bcl-2, an antiapoptotic member of Bcl-2 
family. The very first evidence that Bcl-2 can protect cells from apoptosis by 
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inhibiting  ER/MC Ca2+  cross-talk, was reported by Baffy et al. in 1993 (47). In a 
later study, Cyt-c release induced by BFA (cyt-c release inducing drug) is blocked by 
both wild type and an ER targeted variant of Bcl-2, indicating its involvement in Ca2+ 
regulated apoptotic cross-talk between the ER and MC (31). Jacobson et al. noticed 
inhibition of apoptosis by over expression of Bcl-2 in cells lacking mitochondrial 
DNA. This suggests a protective effect of Bcl-2, independent of mitochondrial 
respiration (39). After this, a number of groups investigated the role of Bcl-2 at the 
ER level. One group reported that Bcl-2 over expression reduced Ca2+  efflux from 
the ER lumen to the cytoplasm, suggesting that Bcl-2 can directly or indirectly 
control the Ca2+ flux across the ER membrane regulating apoptotic Ca2+ signals (40). 
Supporting this, other groups found that Bcl-2 overexpression can reduce the steady 
state Ca2+ concentration in the ER and also Ca2+ influx rate which is activated by Ca2+ 
store depletion while increasing the Ca2+ permeability of the ER membrane (34, 36, 
42-44). However others reported, that Bcl-2 can inhibit apoptosis by maintaining Ca2+ 
influx thus preserving [Ca2+]ER in thapsigargin (Ca2+ pump inhibitor) treated cells 
(41). Overall, these studies prove the capability of Bcl-2 to control Ca2+ signaling 
thus protecting cells while residing in the ER.  
Since both reduction or preservation of [Ca2+]ER  is seen, Bcl-2 should have 
different mechanisms to control influx/efflux of Ca2+ across the ER membrane 
depending upon the condition of the apoptotic cell. However, the underlying 
mechanisms are still not clear and under investigation. There are evidence that Bcl-2 
can control Ca2+ level in ER through interaction with other Bcl-2 family members 
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(36,38).There are reports that the phosphorylation /dephosphorylation status of Bcl-2 
is important in reducing the steady state Ca2+ concentration in the ER. 
Phosphorylation of Bcl-2 inhibits its ability to lower [Ca2+]ER (82). Protein 
Phosphatase 2A (PP2A) has been identified as a regulator of phosphorylation of Bcl-2 
at the ER membrane (81). Ability of Bcl-2 to form ion channels in membranes is 
believed to be another important means for controlling [Ca2+]ER  (15,27,43,49,66-70). 
However, Chami et al. found that the reduction of [Ca2+]ER  by Bcl-2 is independent 
of the putative pore forming domains (α5 and α6)(36). Antioxidant properties of Bcl-
2 at ER are also reported (48). Also it is evident that Bcl-2 can regulate [Ca2+]ER  
through physical and functional interactions with other ER proteins (50-58). Bcl-2 is 
reported to interact with IP3R, calcium release channels in the ER membrane, thereby 
inhibiting Ca2+ release through the channel (50). Calcineurin (PP2B), a calmodulin-
dependent protein phosphatase, dephosphorylates IP3R, reducing Ca2+ leak and Bcl-2 
is reported to directly interact with this calcineurin-IP3R complex (51, 52). Another 
important interaction partner of Bcl-2 at ER is SERCA, the calcium pump in the ER 
membrane (54-56). This SERCA/Bcl-2 interaction is the subject of the work reported 
in this dissertation.  
 
1.4: SRECA/Bcl-2 interactions and objectives of this work. 
Physical interaction of Bcl-2 with SERCA was first reported by Kuo et.al. in 
1998 using immunoprecipitation (54). Recently Dremina et al. were also able to co-
immunoprecipitate SERCA1, fast-twitch skeletal muscle isoform, with both full-
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length Bcl-2 and truncated form, Bcl-2Δ21. They also reported irreversible 
inactivation and translocation of SERCA from caveolae-related domains (CRD) of 
the SR membrane as a result of the interaction with Bcl-2 (55, 56). 
Based on above mentioned studies, direct physical and functional interaction 
of Bcl-2 with SERCA is obvious. However, very little/nothing is known to date, 
about the characteristics of this interaction. Therefore characterization of 
SERCA/Bcl-2 interaction is undoubtedly a huge contribution to the knowledge of 
anti-apoptotic mechanisms of Bcl-2. This understanding would in turn be a new area 
of research for pharmacologists in discovering novel therapeutics for treating 
apoptosis resistant, Bcl-2 overexpressing pathological conditions such as cancer. This 
necessity of understanding SERCA/Bcl-2 interaction set the following objectives of 
the work reported in this dissertation; 
1. Characterization of the site/sites of SERCA involved in the interaction. 
2. Identification of residues/domains of Bcl-2 which are critical for this 
interaction.   
The analytical strategies used to fulfill the above objectives and the results 
will be discussed in the following chapters. 
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Chapter 2:  
Interactions of Bcl-2 with SERCA; Using wild type Bcl-2. 
 
2.1: Introduction to the analytical strategies. 
2.1.1: Cross-linking in protein-protein interaction studies. 
 Cross-linking is an important method which has been used in studies of 
protein interactions for decades. In this method, interaction partners are covalently 
bound to each other using a suitable cross-linking reagent. In general, the reaction 
involves two steps. First, one of the interaction partners is labeled with the selected 
cross-linking reagent. Next the second interaction partner is added in the form of 
purified protein or a mixture of proteins such as a cell lysate and the proteins are 
allowed to associate with each other. Then cross-linking is initiated after the proteins 
are assumed to be associated. Cross-linking results in a covalent bond connecting the 
interfaces involved in the interaction. The covalent bond keeps the proteins/interfaces 
connected during the course of analysis.  
The analysis of the cross-linked products reveals information at three levels; 
(1) Identification of the interacting proteins, (2) Identification of the 
domains/interfaces and (3) Identification of the exact residues involved in the 
interactions. This information gives insight into the architecture of protein complexes, 
which is important in understanding the specific function of a protein complex. 
Cross-linking is used successfully to study transient or low affinity interactions which 
are otherwise difficult to detect and define. The cross-linking reagents contain 
different functionalities that specifically react with amines, thiols or acidic groups in 
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amino acid residues. Usually a reagent contains two functional groups connected by a 
spacer arm. These reagents are categorized based on their functionalities. 
Homobifunctional cross-linking reagents have the same terminal activated groups 
while the two groups are different in heterobifunctional reagents, making possible 
reaction with different functional groups in the proteins. In addition, these reagents 
are developed with a wide range of spacer arm lengths. Selection of the proper cross-
linking reagent is critical for a successful analysis. The selected reagent should 
efficiently cross-link the interfaces without significant alterations in the interaction (1-7). 
 
(a) Photo cross-linking:  
Photo cross-linking reagents are a group of heterobifunctional reagents in 
which one functional group is photoactivatable whereas the other functional group is 
a chemically reactive group with a thiol (sulfhydryl), amine or acidic group 
specificity. The photophore moiety of an effective photo cross-linker must be 
chemically inert prior to the photoactivation. Also it should be activatable under mild 
conditions not damaging the protein complex. The lifetime of the excited state of the 
photophore should be shorter than the off-rate of the protein complex. Further the 
excited photophore should nonspecifically react with any amino acid residue in close 
proximity to form a covalent bond. Due to these properties, unlike the other 
bifunctional cross-linkers, the photo cross-linkers provide a measure of control over 
the reaction (1, 2, 5). 
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SCHEME 2.1: Benzophenone-4-maleimide (BPM): (a) Structure of BPM, (b) 
Reaction of a Maleimide group with a thiol (sulfhydryl) group; R1-benzophenone 
group, R2-protein with a thiol group, (c) Reaction of a Benzophenone group upon 
photo activation. (Adapted from www.probes.com) 
 
Benzophenone-4-maleimide (BPM) was the photo cross-linking reagent used 
in this study for characterization of SERCA/Bcl-2 interactions. This is a 
commercially available reagent and has all the favorable properties explained above. 
Scheme 2.1-a shows the structure of BPM and the chemistries associated with cross-
linking reactions. It has a thiol reactive maleimide group and a photoactivatable 
benzophenone group. The maleimide group reacts with a thiol group producing a 
thioether bond (Scheme 2.1-b). Benzophenone group can be photo activated at ~350 
      Benzophenone group 
(a) 
(c) 
(b) 
Maleimide group 
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nm of UV light and once excited it reacts with any neighboring CH-bond (Scheme 
2.1-c). Since this biradical formation upon photoactivation is a reversible reaction, 
cross-linking is more efficient (2, 8). 
Photo cross-linking of interacting proteins is achieved in two steps. First, one 
of the interacting proteins is labeled with the cross-linking reagent, BPM in this 
study. Next the second protein is added and the two proteins are allowed to interact 
with each other followed by irradiation with UV light, triggering the covalent bond 
formation. Finally the cross-linked products are analyzed using a suitable analytical 
method. These steps are shown in Figure 2.1, using BPM as the cross-linking reagent. 
 
 
 
FIGURE 2.1: Photo cross-linking of interacting proteins using BPM: First, protein-
1 is labeled with BPM. Next protein-2 is added and the two proteins are allowed to 
interact with each other followed by irradiation with UV light, triggering the covalent 
bond formation. Cross-linked products can be analyzed using a suitable analytical 
method such as western blotting and/or mass spectrometry.  
 
 
UV irradiation 
Protein 1 + BPM 
Enzymatic 
digestion
BPM 
Identification of cross-linked 
products by MS. 
Western blot analysis of cross-linked 
proteins. 
Protein 1 + BPM Protein 2
BPM Protein 1 Protein 2
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SCHEME 2.2: Chemical cross-linking reagents: (a) Structures of heterobifunctional 
cross-linking reagents, N-[β-maleimidopropyloxy]succinimide ester (BMPS), m-
maleimidobenzoyl-N-hydroxysuccinimide ester (MBS), Succinimidyl 4-(N-
maleimidomethyl)cyclohexane-1-carboxylate (SMCC) and Succinimidyl-6-[(β-
maleimidopropionamido)hexanoate (SMPH). (b) Reaction of the Maleimide group 
with a thiol (sulfhydryl) group. (c) Reaction of the NHS ester group with an amine 
group. (Adapted from Cross-linking Reagents-Technical Handbook, 
www.piercenet.com) 
 
BMPS 
Spacer arm 5.9 Å 
MBS 
Spacer arm 7.3 Å 
SMCC 
Spacer arm 11.6 Å 
SMPH 
Spacer arm 14.2 Å 
(a) 
(c) 
(b) 
Sulfhydryl-
containing 
molecule 
Maleimide 
compound 
Thioether bond 
Amine-containing 
molecule 
NHS ester 
compound 
Amide bond NHS 
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(b) Chemical  cross-linking: 
Chemical cross-linking was also used to characterize SERCA/Bcl-2 
interactions. The four heterobifunctional cross-linking reagents, N-[β-
maleimidopropyloxy]succinimide ester (BMPS), m-maleimidobenzoyl-N-
hydroxysuccinimide ester (MBS), Succinimidyl 4-(N-maleimidomethyl)cyclohexane-
1-carboxylate (SMCC), and Succinimidyl-6-[(β-maleimidopropionamido)hexanoate 
(SMPH) used in the study are shown in Scheme 2.2-a. All these four reagents have a 
thiol (sulfhydryl) reactive maleimide group and an amine reactive N-
hydroxysuccinimide (NHS) ester group and spacer arm lengths ranging from 5.9 Å -
14.2 Å. The chemistries of the two functionalities are also shown in the Scheme 2.2-
b, c (9). 
 
2.1.2: Bcl-2Δ21 and His6-Bcl-2Δ17. 
 A truncated form of Bcl-2, Bcl-2Δ21, purified from GST-Bcl-2Δ21 fusion 
protein and also the commercially available truncated and hexahistidine tagged Bcl-2, 
His6-Bcl-2Δ17, were used in photo cross-linking studies. Both these proteins contain 
only one thiol (sulfhydryl) group at Cys158 and the photo cross-linking reagent, BPM 
was attached to this site. The advantage of the His6-Bcl-2Δ17 is the ability to purify 
cross-linked products using affinity chromatography. Ni2+ or Co2+ chelated affinity 
resins can be used to trap His6-Bcl-2Δ17 and the trapped proteins can be eluted with 
high concentrations of imidazole. This makes the reaction mixture less complex and 
the identification of cross-linked proteins easier.   
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2.1.3: Monitoring cysteine derivatization efficiency of Bcl-2Δ21.  
 For an effective cross-linking reaction, thiol reactive cross-linking reagents 
should efficiently react with the cysteine group of Bcl-2Δ21, Cys158. To monitor the 
efficiency of Cys158 derivatization, a maleimide-based fluorescent reagent, ThioGlo1 
was utilized. Free cysteines react with this reagent producing fluorescent ThioGlo1-
cysteine adducts. The intensity of the fluorescence indicates the amount of free 
cysteine in the sample.  
 
2.1.4: Analysis of cross-linked products. 
After covalently connecting the pairs of functional groups of interacting 
proteins, the products are subjected to suitable analytical procedures. Mass 
spectrometry and western blotting were the methods of choice in this study. 
 
(a) Mass spectrometry in cross-linking studies:  
  Mass spectrometry is a state-of-the-art analytical method which has been used 
successfully in combination with cross-linking, to study protein interactions in recent 
years. After the cross-linking reaction the products are isolated and enzymaticaly 
digested. The resulting mixture of peptides is subjected to MS analysis (10-18). This 
is called “Bottom-up strategy” for the analysis of cross-links and all the associated 
steps are schematically shown in Figure 2.2 (19).  The assignment of the cross-linked 
peptides is done manually or using software programs (20, 21). Using tandem mass  
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FIGURE 2.2: Bottom-up strategy for the analysis of protein cross-links: Both 
inter- or intra-molecularly cross-linked proteins can be analyzed. SDS-PAGE or size 
exclusion chromatography is used to isolate cross-linked products. LC/MS is used to 
analyze cross-linked products after enzymatic in-gel or in-solution digestion. 
MALDI-MS can be used to monitor the extent of cross-linking prior to the digestion 
of products. (Figure adapted from Sinz, A. (2005) Anal. Bioanal. Chem. 381, 44-47.) 
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spectrometry (MS/MS) the exact cross-linking site/sites can be determined. The 
masses of the proteins involved in the interaction do not affect the MS analysis, since  
proteolytic peptides are analyzed. Another associated advantage is, even a femtomole 
amount of cross-linked product is enough for analysis due to the higher sensitivity of 
the modern MS instruments. In this study, ESI-FTICR-MS was used to analyze cross-
linked products after 1D-SDS-PAGE and in-gel tryptic digestion. FTICR-MS allows 
unambiguous assignment of cross-linked peptides and exact cross-linking 
sites/residues as well, due to the higher accuracy and resolution and also the MS/MS 
ability of the instrument (15-18). 
 
(b) Western blotting in cross-linking studies:  
  Western blotting is a classical, yet very useful method for analysis of cross-
linked proteins. After the cross-linking reaction, the mixture is fractionated using 
SDS-PAGE and transferred onto a nitrocellulose membrane. Then the cross-linked 
proteins are probed using antibodies raised against the protein/proteins of interest. 
Comparing the cross-linking reaction sample with appropriate control samples in the 
western blot, cross-linked products can be identified (22). The expected SERCA/Bcl-
2 cross-linked products are shown in the simulated western blots in Figure 2.3. 
 
2.1.5: GST-Bcl-2Δ21 binding assay. 
 Detailed introduction of this assay is presented in the Chapter 3 since most of 
the binding assay experiments are related to that chapter. 
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FIGURE 2.3: Simulated western blots of SERCA/Bcl-2 cross-linking reaction 
samples: (a) With Bcl-2 antibody. (b) With SERCA antibody. If the molecular ratio 
between SERCA (~110 kDa) and Bcl-2 (25 kDa) is 1:1 and/or 1:2, bands at ~135 kDa 
and/or ~160 kDa are seen only with the cross-linking reaction sample, Bcl-
2/Linker/SR but not with the two control samples, Bcl-2/Linker and SR/Linker.  
 
 
2.2: Materials and methods. 
2.2.1: Bcl-2Δ21 expression and purification.  
(a) Expression of Bcl-2Δ21: 
  The E.coli host strain containing the pGEX3T vector of GST-Bcl-2Δ21 fusion 
protein was available in the lab (Clone of human Bcl-2Δ21 needed  for GST-Bcl-
2Δ21 plasmid construction has been kindly provided by Prof. S. J. Korsmeyer, 
Harvard Medical School, Boston, MA, U.S.A.). The protein expression and 
purification protocol was adapted from Dremina et al. (23). A 1 liter of Luria-Bertani 
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(LB) medium was inoculated with a 10 ml of overnight culture and further incubated 
at 37°C with vigorous shaking at 220 rpm until the optical density, A600, reached 0.4. 
Isopropyl β-D-thiogalactoside (0.1 mM)  (IPTG) (American Bioanalytical, Natick, 
MA, U.S.A.) was added to induce the expression of GST-Bcl-2Δ21 and further 
incubated at 32°C with vigorous shaking at 220 rpm for another 6 hours.  The cells 
were harvested by centrifugation and stored at -20°C until used.  
 
(b) Purification of  Bcl-2Δ21: 
For the purification of GST-Bcl-2Δ21, the cell pellet was re-suspended in ice-
cold STE buffer (Tris-buffered saline) containing 7.5 mM Tris (pH 8.0), 150 mM 
NaCl and 3 mM EDTA. The cell suspension was incubated with Lysozyme (0.1 
mg/ml) on ice for 20 min. It was sonicated in the presence of 1.5% (w/v) Sarkosyl 
(Fisher BioReagents, U.S.A.), 5 mM DTT, 100 μM Phenylmethylsulfonyl fluoride 
(PMSF) (Sigma, St. Louis, MO) and 1 mM Benzamidine. Resulting cell lysate was 
centrifuged at 15000g for 40 min at 4°C to pellet the cell debris. The supernatant was 
incubated with 500 μl (250 μl of bed volume) of slurried Glutathione-agarose beads 
(Sigma, St. Louis, MO, U.S.A.) in the presence of 2% Triton X-100 for 3 h at 4°C 
with gentle rotation. The beads were spun down and washed six times with 1 ml 
portions of STE buffer containing 1% Triton X-100, then two additional times with 1 
ml portions of STE buffer without Triton X-100. The beads were resuspended in 250 
μl of STE, incubated with 5 units of Thrombin for 1 h at room temperature to cleave  
GST-Bcl-2Δ21, then spun down. The supernatant was incubated with 10 μl of pre-
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washed thrombin-binding beads (Sigma, St. Louis, MO, U.S.A.) for 15 min at 4°C. 
The mixture was centrifuged to separate the supernatant of 250 μl of STE containing 
purified Bcl-2Δ21. This procedure yielded ca. 75 µg of Bcl-2Δ21 (250 μl of 0.3 
mg/ml) per liter of LB medium as measured by the Coomassie Plus protein assay 
(Pierce, Rockford, IL, U.S.A.). Purified proteins were subjected to SDS-PAGE and 
analyzed by western blotting with mouse monoclonal anti-Bcl-2 antibody (sc-7382, 
Santa Cruz Biotechnology, Santa Cruz, CA, U.S.A.). The SDS-PAGE and western 
blotting procedure is explained in the section 2.2.12.  
 
(c)Bcl-2Δ21 Storage Conditions:  
In order to find the best storage conditions for the purified protein, a set of six 
samples of Bcl-2Δ21 were prepared as follows by mixing freshly purified protein 
with two protease inhibitors; 1 mM (1), 0.5 mM (2) and 0.1 mM (3) of PMSF and 1 X 
(4) and 0.5 X (5) of protease inhibitors cocktail (Roche Diagnostics, Indianapolis, IN, 
U.S.A.), respectively and control sample (6), without any protease inhibitors added. 
The samples were stored at -20°C. Another set of samples prepared in the same way 
were stored at 4°C. A fraction of each sample was subjected to SDS-PAGE and 
Coomassie Blue staining after 18 h, 1 week, and 2 weeks of storage.  
 
2.2.2: Isolation of SR Vesicles. 
Native SR vesicles, isolated from hind limb skeletal muscles of Fisher 344 
rats according to the procedure by Fernandez et al. (24), were kindly provided by Dr. 
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E. Dremina (Department of Pharmaceutical Chemistry, University of Kansas, KS, 
U.S.A.). According to Dremina et al. (25) these purified SR vesicles contain ca. 40% 
of SERCA1 as determined by densitometry of Coomassie Blue-stained gels. 
 
2.2.3: Optimization of BPM labeling reaction conditions.  
(a) Optimum reaction time:   
Samples of Bcl-2Δ2 were prepared with the final concentration of 5 μM in 
STE (pH 7.5) buffer and incubated with 50 μM BPM (Sigma, St. Louis, MO), at 
room temperature with stirring, for 30 min and for 1 h separately. The samples were 
incubated with 20 μM ThioGlo1 (Covalent Associates, Woburn, MA, U.S.A.), for 1 h 
at 37°C in 200 mM phosphate buffer (pH 7.4). The control sample was prepared in 
the same way but without incubation with BPM. 1 ml of each of these samples was 
used to measure the fluorescence of ThioGlo1-cysteine adducts, at excitation and 
emission wavelengths of 379 nm and 513 nm, respectively. Shimadzu RF5000U 
fluorescence spectrophotometer was used for measurements.  
 
(b) Effect of the redox status of Bcl-2Δ2 cysteine:   
Samples of Bcl-2Δ2 (7.5 µM) were incubated both with and without 15 µM 
DTT for 30 min at room temperature with stirring followed by dialysis with STE (pH 
7.5) buffer over night using 3500 MWCO Slide-A-Lyzer MINI dialysis units (Pierce, 
Rockford, IL). Then the samples were incubated with 20 μM ThioGlo1 for 1 h at 
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37°C in 200 mM phosphate buffer (pH 7.4) and the fluorescence was measured in the 
same way as above.  
 
(c) Effect of native and denatured Bcl-2Δ21:  
Two samples of Bcl-2Δ2 (0.5 μM) in STE (pH 7.5) buffer were incubated 
with 5 μM of BPM, at room temperature with stirring, for 30 min in the presence and 
absence of 2% SDS (w/v). The control samples, with Bcl-2Δ2/without BPM and 
without Bcl-2Δ2/with BPM were prepared in the same way. All the samples were 
incubated with 20 μM ThioGlo1 for 1 h at 37°C in 200 mM phosphate buffer (pH 
7.4). Fluorescence was measured in the same way as above.  
 
(d) Effect of mild denaturing agents:  
Samples of Bcl-2Δ2 (0.5 μM) in STE (pH 7.5) buffer containing 1, 5, 10, 15% 
Nonidet P40 (NP-40) (w/v) and also 0.2% CHAPS (w/v) were incubated first, for 30 
min in the presence or absence of 5 μM of BPM at room temperature with stirring, 
next for another 1 h at 37°C with 20 μM ThioGlo1 (Covalent Associates, Woburn, 
MA, U.S.A.), in 200 mM phosphate buffer (pH 7.4). Fluorescence was measured in 
the same way as above.  
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(e) Lowest effective concentration of SDS: 
Samples of Bcl-2Δ2 (1 μM) were incubated  with 20 μM ThioGlo1 for 1 h at 37°C in 
200 mM phosphate buffer (pH 7.4) containing 0, 0.05, 0.1, 0.2, 0.5, 0.75 and 1% SDS 
(w/v), respectively and the fluorescence was measured in the same way as above.  
 
(f) Comparison of Bcl-2Δ2 and His6-Bcl-2Δ17 in cysteine derivatization: 
Bcl-2Δ2 and His6-Bcl-2Δ17 with the final concentrations of 0.3 μM were 
incubated with 20 μM ThioGlo1 for 1 h at 37°C in 200 mM inorganic phosphate 
buffer (pH 7.4) in the presence and absence of 0.2% SDS (w/v) and the fluorescence 
was measured in the same way as above.  
 
2.2.4: Labeling Cys158 of Bcl-2Δ21/ His6-Bcl-2Δ17 using optimized conditions.  
Bcl-2Δ21/His6-Bcl-2Δ17 (4 µM) was incubated with 40 µM BPM for 30 min 
at room temperature with stirring, in the presence of 0.05% of SDS in STE buffer (pH 
7.5).  DMF (Dimethylformamide) was added to the mixture so that the contribution of 
organic solvent to the final reaction mixture was only 8%. Then 400 µM of DTT was 
added to react with excess BPM and incubated at room temperature with stirring for 
another 10 min. Sample was dialyzed with 2 L of  STE (pH 7.5) for 4 h using 3500 
MWCO Slide-A-Lyzer MINI dialysis units (Pierce, Rockford, IL). The buffer was 
changed after first two hours. Alternatively, ZebaTM Desalt Spin Columns (Pierce, 
Rockford, IL, U.S.A.) or 10k MWCO Microcon Centrifugal Filter Devices (Millipore 
Corporation, Bedford, MA, U.S.A.) were used. After dialysis/spin columns/micro 
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filtration, the protein concentration was determined using Coomassie Plus protein 
assay (Pierce, Rockford, IL).  In all above steps precautions were taken to prevent 
exposure of samples to light. In the case of His6-Bcl-2Δ17 (EMD Biosciences, San 
Diego, CA), 8 µM His6-Bcl-2Δ17 and 80 µM BPM was used and all the reaction 
steps were the same. BPM labeling reaction sample was characterized as explained 
below in section 2.2.5.  
 
2.2.5: Characterization of BPM labeling reaction samples. 
(a) RP-HPLC separation of BPM labeling reaction mixture: 
100 µL of BPM labeling reaction mixture was loaded into a Vydac C4 column 
(250×4.6mm i.d.), pre-equilibrated with 10% ethanol (v/v) in 0.1% aqueous TFA. 
Products on the column were eluted at a flow rate of 0.5 mL/min using a linear 
gradient,  increasing  ethanol  percentage by 1.5%/min. Chromatograms were 
recorded at 280 nm (for protein detection) and 260 nm (λmax of thiol conjugated 
BPM). 
 
(b) Mass spectrometric analysis of BPM labeling reaction mixture: 
BPM labeling reaction samples were subjected to SDS-PAGE and analyzed 
by ESI-FTICR-MS after in-gel tryptic digestion. In-gel tryptic digestion procedure is 
explained in section 2.2.14. 
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(c) Effect of BPM treated Bcl-2Δ21 on Ca2+-ATPase activity of SERCA: 
  Concentrated SR vesicle suspension (ca. 20 mg of SR protein/ml) was diluted 
in STE buffer (pH 7.5), the buffer used for BPM labeling of Bcl-2Δ21, so that the 
contribution from the SR storage buffer is <5%.  The final concentration of SR 
proteins in this sample was 0.35 mg/mL. BPM treated or none treated Bcl-2Δ21 was 
added into the diluted SR sample with the final concentration of 0.17 mg/ml. The 
control samples of SR without Bcl-2Δ21 were also prepared in the same way. All the 
samples were incubated in 1.5 mL Eppendorf tubes at 37oC for 3 h using a dry 
thermostat without agitation.  Protease inhibitor, PMSF (1 mM) was added to each 
sample to prevent proteolytic degradation.  
The Ca2+ dependent ATPase activity assay procedure was adapted from 
Dremina et al. (23). Briefly, total and basal ATPase activities of SERCA in the 
sample were measured at 25oC using a colorimetric assay for inorganic phosphate (Pi) 
(26). Basal activity was subtracted from the total activity to obtain Ca2+ dependent 
ATPase activity. This measured activity is the Ca2+ dependent ATPase activity of 
SERCA in the sample since it has been shown before that this activity can be 
completely inhibited by the addition of thapsigargin, well known inhibitor of SERCA 
(23).  The Ca2+ dependent ATPase activity of SERCA of the three samples was 
measured both before and after the incubation at 37oC for 3 h. 
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2.2.6: Optimization of photo cross-linking reaction conditions. 
(a) Molar ratio between SERCA and Bcl-2Δ21: 
The photo cross-linking reaction samples of Bcl-2Δ21/BPM/SR were 
prepared by mixing BPM treated Bcl-2Δ21 with purified SR vesicles in STE (pH 7.5) 
buffer so that the molar ratios between Bcl-2Δ21 and SERCA were 10:1, 5:1, 2:1, 
1:1, 1:2 and 1:5, respectively. The control sample of Bcl-2Δ21/BPM was prepared 
using the same amount of BPM treated Bcl-2Δ21 without SR. For the control sample 
of SR/BPM,   40 µM BPM in the buffer (pH 7.5 STE buffer, 0.05% SDS, 8% DMF) 
without Bcl-2Δ21 was subjected to the same BPM labeling reaction  steps followed 
by the addition of  the same amount of SR. Protease inhibitor PMSF (1 mM) was 
used in each sample to prevent  proteolytic degradation. All the samples were 
incubated in 1.5 mL Eppendorf tubes at 37oC for 1 h using a dry thermostat without 
agitation. After incubation, the samples were transferred into quartz tubes and 
irradiated with 350 nm UV light for 30 min using a Rayonet photochemical reactor 
(The Southern New England Ultraviolet Company). Finally the samples were boiled 
for 5 min with sample buffer (2% SDS, 10% glycerol, and 125 mM Tris pH 6.8) and 
analyzed by western blotting after SDS-PAGE.  
 
(b) Incubation time for SERCA and Bcl-2Δ21: 
The photo cross-linking reaction samples of Bcl-2Δ21/BPM/SR were 
prepared by mixing BPM treated Bcl-2Δ21 with purified SR vesicles in STE (pH 7.5) 
buffer so that the molar ratio between Bcl-2Δ21 and SERCA was 2:1. The control 
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sample of Bcl-2Δ21/BPM was prepared using the same amount of BPM treated Bcl-
2Δ21 without SR. For the control sample of SR/BPM,   40 µM BPM in the buffer (pH 
7.5 STE buffer, 0.05% SDS, 8% DMF) without Bcl-2Δ21 was subjected to the same 
BPM labeling reaction  steps followed by the addition of  the same amount of SR. 
Protease inhibitor PMSF (1 mM) was used in each sample to prevent  proteolytic 
degradation. Samples were incubated in 1.5 mL Eppendorf tubes at 37oC using a dry 
thermostat without agitation for 2 h, 1 ½ h, 1 h, 45 min, 30 min, 15 min and 5 min. 
After incubation, samples were transferred into quartz tubes and irradiated with 350 
nm UV light for 30 min using a Rayonet photochemical reactor (The Southern New 
England Ultraviolet Company). Finally the samples were boiled for 5 min with 
sample buffer (2% SDS, 10% glycerol, and 125 mM Tris pH 6.8) and analyzed by 
western blotting after SDS-PAGE.  
 
2.2.7: Photo cross-linking of BPM treated Bcl-2Δ21/His6-Bcl-2Δ17 with SERCA 
using optimized reaction conditions.  
Bcl-2Δ21/BPM/SR sample was prepared by mixing BPM treated Bcl-2Δ21 
with purified SR vesicles in STE (pH 7.5) buffer so that the final concentrations were 
1.4 µM and 0.7 µM, respectively, and the molar ratio between Bcl-2Δ21 and SERCA 
was 2:1.  BPM treated Bcl-2Δ21 (1.4 µM) was diluted in STE (pH 7.5) buffer without 
SR for the control sample of Bcl-2Δ21/BPM. For the control sample of SR/BPM,   40 
µM BPM in buffer (pH 7.5 STE buffer, 0.05% SDS, 8% DMF) without Bcl-2Δ21 
was subjected to the same BPM labeling reaction  steps followed by addition of SR 
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with the same 0.7 µM final concentration  of SERCA. Protease inhibitor PMSF (1 
mM) was used in each sample to prevent proteolytic degradation. All three samples 
were incubated in 1.5 mL Eppendorf tubes at 37oC for 15 min using a dry thermostat 
without agitation. After incubation, samples were transferred into quartz tubes and 
irradiated with 350 nm UV light for 30 min using a Rayonet photochemical reactor 
(The Southern New England Ultraviolet Company). Finally the samples were boiled 
for 5 min with sample buffer (2% SDS, 10% glycerol, and 125 mM Tris pH 6.8). 
Samples were analyzed by Coomassie Blue staining and western blotting after SDS-
PAGE. In addition mass spectrometry was also used after SDS-PAGE and in-gel 
tryptic digestion. Photo cross-linking reaction samples using His6-Bcl-2Δ17, were 
subjected to Ni2+ affinity purification as explained below and fractions collected were 
boiled for 5 min with sample buffer before SDS-PAGE and western blot analysis. 
 
2.2.8: Ni2+ affinity purification of photo cross-linked products of His6-Bcl-2Δ17.  
A HisTrapHP (1 ml) Ni2+ affinity column (GE Healthcare, UK) was used to 
affinity purify cross-linked products. First the column was washed with 6 ml of 
distilled water to remove the storage solution. Then the column was equilibrated with 
six column volumes (6 ml) of the binding buffer, 2 mM imidazole. Cross-linking 
reaction samples, diluted in 1 ml of binding buffer, were injected to the column and 
the column was washed with binding buffer. Proteins bound to the column were 
eluted with increasing concentrations of imidazole, 50 mM (2 ml), 100 mM (2 ml) 
and 500 mM (3 ml) and fractions were collected.  Cross-linking reaction samples 
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were run through the column in the order of SR/BPM, His6-Bcl-2Δ17/BPM and His6-
Bcl-2Δ17/BPM/SR and the column was washed with water, re-equilibrated with the 
binding buffer between each run. 
 
2.2.9: Chemical cross-linking of Bcl-2Δ21 with SERCA.  
(a) Starting with Bcl-2Δ21:  
STE buffer in purified Bcl-2Δ21 was exchanged with PBS buffer (pH 7.2, 0.1 
M Sodium phosphate, 0.15 M NaCl and 5 mM EDTA) using 10k MWCO Microcon 
Centrifugal Filter Devices (Millipore Corporation, Bedford, MA, U.S.A.) and the 
concentration was determined using Coomassie Plus protein assay (Pierce, Rockford, 
IL). Reaction samples were prepared by mixing Bcl-2Δ21 (7.5 μM) with 0.75 mM of 
chemical cross-linking reagent, BMPS, MBS, SMCC or SMPH (Pierce, Rockford, IL, 
U.S.A.) separately, so that the Bcl-2Δ21:linker ratio is 1:100 (mol/mol). Organic 
solvent, DMSO, was 4% (v/v) in each sample. All samples were incubated for 30 min 
at room temperature with stirring. Samples were run through ZebaTM Desalt Spin 
Columns (Pierce, Rockford, IL, U.S.A.) and the protein concentration was 
determined. Each sample was split into two fractions and Bcl-2Δ21/Linker/SR 
samples were prepared by diluting SR vesicles in one fraction so that the molar ratio 
between SERCA and Bcl-2Δ21 was 1:2. The other fraction was Bcl-2Δ21/Linker 
without added SR. For SR/Linker samples, 0.75 mM of chemical cross-linking 
reagent (BMPS, MBS, SMCC or SMPH) in the buffer (PBS pH 7.2, 0.1 M sodium 
phosphate, 0.15 M NaCl and 5 mM EDTA, 4% DMSO) without Bcl-2Δ21 was 
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subjected to the same reaction steps followed by the addition of the same amount of 
SR. Samples were incubated in 1.5 mL Eppendorf tubes at 37oC for 30 min using a 
dry thermostat without agitation. Finally the samples were boiled for 5 min with 
sample buffer (2% SDS, 10% glycerol, and 125 mM Tris pH 6.8) and analyzed by 
western blotting after SDS-PAGE. In a separate experiment 1:20 (mol/mol) of Bcl-
2Δ21: linker ratio was used and all other steps were the same. 
 
(b) Starting with SERCA:  
SR was diluted in PBS buffer to a final SERCA concentration of 2.5 μM and 
mixed with chemical cross-linking reagent (0.25 mM) (BMPS, MBS, SMCC or 
SMPH) separately, so that the SERCA:linker ratio is 1:100 (mol/mol). Organic 
solvent, DMSO, was 4% (v/v) in each sample. All samples were incubated for 30 min 
at room temperature with stirring. Samples were run through ZebaTM Desalt Spin 
Columns (Pierce, Rockford, IL, U.S.A.) and protein concentration was determined. 
Each sample was split into two fractions and SR/Linker/Bcl-2Δ21 sample was 
prepared by adding Bcl-2Δ21 (in PBS buffer) into one fraction so that the molar ratio 
between SERCA and Bcl-2Δ21 was 1:2. The other fraction was the control sample of 
SR/Linker without added Bcl-2Δ21. For Bcl-2Δ21/Linker samples, 0.25 mM of 
chemical cross-linking reagent (BMPS, MBS, SMCC or SMPH) in the buffer (PBS 
pH 7.2, 0.1 M sodium phosphate, 0.15 M NaCl and 5 mM EDTA, 4% DMSO) 
without SR was subjected to the same reaction  steps followed by the addition of  the 
same amount of Bcl-2Δ21 as in the experimental samples. Samples were incubated in 
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1.5 mL Eppendorf tubes at 37oC for 30 min using a dry thermostat without agitation. 
Finally the samples were boiled for 5 min with sample buffer (2% SDS, 10% 
glycerol, and 125 mM Tris pH 6.8) and analyzed by western blotting after SDS-
PAGE. 
 
2.2.10: Analysis of other possible SR proteins associated with Bcl-2 or SERCA. 
(a)Using western blotting: 
Ni2+ affinity chromatographic fractions of photo cross-linking samples of 
His6-Bcl-2Δ17 were subjected to western blot analysis with antibodies raised against 
Glycogen Phosphorylase, Sarcalumenin, Mitsugumin-29 and Calcium Channel (α2/δ-
1 subunit), after SDS-PAGE. 
 
(b)Using GST- Bcl-2Δ21 binding assay: 
  For the GST-Bcl-2Δ21 binding assay, 100 µg of SR were solubilised in 150 
µL of lysis buffer (10 mM Tris (pH 7.4), 10 mM EDTA, 1% Nonidet P40 (NP40), 
1mM PMSF and protease inhibitors (Roche Diagnostics)). This mixture was 
incubated with 10 µg of GST-Bcl-2Δ21 for 2 h at 4oC. For a control, another 100 µg 
of SR in 150 µL of lysis buffer were incubated without GST-Bcl-2Δ21. Then all the 
samples were incubated with 30 µL of (packed volume) pre-washed glutathione–
agarose beads, for another 2 h at 4oC. The beads were spun down at 10000g and 
washed three times with lysis buffer and three times with STE. Addition of 30 µL of 
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STE was followed by boiling for 5 min with sample buffer (2% SDS, 10% glycerol, 
125 mM Tris pH 6.8) and by SDS-PAGE and western blot analysis. 
 
2.2.11: Comparison of young and old SERCA in photo cross-linking with Bcl-2Δ21. 
SR vesicles purified from tissues of both young (5-6 months) and old (34 
months) rats were used to prepare samples. Bcl-2Δ21/BPM/SR sample was prepared 
by mixing BPM treated Bcl-2Δ21 with purified SR vesicles in STE (pH 7.5) buffer so 
that the final concentrations were 1.4 µM and 0.7 µM, respectively, and the molar 
ratio between Bcl-2Δ21 and SERCA was 2:1.  BPM treated Bcl-2Δ21 (1.4 µM) was 
diluted in STE (pH 7.5) buffer without SR for the sample of Bcl-2Δ21/BPM. For the 
SR/BPM sample,   40 µM BPM in the buffer (pH 7.5 STE buffer, 0.05% SDS, 8% 
DMF) without Bcl-2Δ21 was subjected to the same BPM labeling reaction  steps 
followed by SR addition with the same 0.7 µM final concentration  of SERCA. 
Protease inhibitor PMSF (1 mM) was used in each sample to prevent proteolytic 
degradation. All three samples were incubated in 1.5 mL Eppendorf tubes at 37oC for 
1 h using a dry thermostat without agitation. After incubation, samples were 
transferred into quartz tubes and irradiated with 350 nm UV light for 30 min using a 
Rayonet photochemical reactor (The Southern New England Ultraviolet Company). 
Finally the samples were boiled for 5 min with sample buffer (2% SDS, 10% 
glycerol, and 125 mM Tris pH 6.8) and analyzed by western blotting after SDS-
PAGE.  
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2.2.12: Details of SDS-PAGE and western blotting.  
Samples boiled with the sample buffer were separated on precast 4-20% 
gradient gels from Bio-Rad Laboratories (Hercules, CA) or Invitrogen (Carlsbad, CA) 
using tris-glycine running buffer. For MS analysis, the gels were stained with 
Coomassie Blue protein staining reagent. For western blot analysis, the gels were 
electroblotted onto 0.45 µm polyvinyldifluoride (PVDF) membrane (Millipore, 
Bedford, MA) and ECL detection kit (GE Healthcare, UK) was used to visualize the 
spots according to the manufacturer’s procedure. 
 
2.2.13: Antibodies. 
 Mouse monoclonal anti-Bcl-2 antibody (sc-7382), Goat polyclonal Anti-
Glycogen Phosphorylase antibody (sc-46347), Mouse monoclonal Sarcalumenin 
antibody (sc-58845) and Goat polyclonal Anti-Mg29 antibody (sc-23441) were 
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-SERCA1 mouse 
monoclonal antibody (MA3-912) was from Affinity Bioreagents (Golden, CO). 
Rabbit Anti-Calcium Channel (α2/δ-1 subunit) antibody (C5105), Secondary 
horseradish peroxidase (HRP)-conjugated anti-rabbit antibodies (A0545) and anti-
goat antibodies (A5420) were from Sigma (St. Louis, MO). Secondary (HRP)-
conjugated anti-mouse antibodies (31437) were from Pierce Biotechnology 
(Rockford, IL).  
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2.2.14: In-gel tryptic digestion procedure. 
The bands of interest were excised from Coomassie Blue stained gels, cut into 
smaller pieces and washed twice with 0.2 M NH4HCO3/50% (v/v) acetonitrile for 45 
min at 37oC. Protein reduction and alkylation was performed by incubating the gel 
pieces first with 10 mM DTT in 0.2 M NH4HCO3 for 30 min at 60oC, followed by 
reaction with 20 mM iodoacetamide for 30 min at room temperature in the dark.  
Discarded the solution, gel pieces were washed with 200 µl of 0.2 M NH4HCO3/50% 
(v/v) acetonitrile and   250 µl of 100% acetonitrile was added to shrink the gel pieces. 
After 15 min, acetonitrile was removed and dried the gel pieces. Then the gel pieces 
were re-swollen  in  20 µl of 0.2 M NH4HCO3 containing 5 mM CaCl2 and  
sequencing grade modified trypsin (Promega, Madison, WI) at an approximate 5:1 
molar ratio of protein to trypsin. 40-50 µl of 0.2 M NH4HCO3/10% (v/v) acetonitrile 
were added to cover the gel pieces and incubated over night (16-18 h) at 37oC. After 
spinning down the gel pieces, the supernatant was submitted to the ESI-FTICR-MS 
facility of the Analytical Proteomics Laboratory, The University of Kansas, for 
analysis. 
 
2.3: Results and Discussion. 
2.3.1: Expression and purification of Bcl-2Δ21.  
 Bcl-2Δ21, a truncated form of human Bcl-2, was expressed in E. coli as a 
GST (Glutathione-S-Transferase) fusion protein. Affinity of GST for GSH 
(glutathione) helps the purification of the fusion protein from the bacterial cell lysate 
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using affinity chromatography. GST-Bcl-2Δ21 has an approximate apparent 
molecular weight of 47 kDa (Figure 2.4-a, lane 2). A thrombin cleavage site is 
located in the fusion protein and the incubation of GST-Bcl-2Δ21, bound to GSH-
agarose beads, with thrombin yields Bcl-2Δ21. Thrombin binding beads help the 
removal of thrombin resulting in purified Bcl-2Δ21. Both GST and Bcl-2Δ21 have 
approximate apparent molecular weights of 25 kDa (Figure 2.4-a, lanes 3 and 4, 
respectively). The purified protein is Bcl-2Δ21 as confirmed by western blotting with 
monoclonal anti-Bcl-2 antibody (Figure 2.4-b).  
 
 
 
FIGURE 2.4: Expression and purification of Bcl-2Δ21: (a) Coomassie Blue staining 
of proteins after SDS-PAGE: lane 1, molecular weight standard; lane 2, GST-Bcl-
2Δ21 bound to GSH-agarose beads; lane 3, purified Bcl-2Δ21; and lane 4, GST 
bound to GSH-agarose beads after thrombin cleavage of GST-Bcl-2Δ21. (b) Analysis 
of purified Bcl-2Δ21 by western blotting with anti-Bcl-2 monoclonal antibody: lanes 
1, 2 and 3 are 0.1, 0.05 and 0.025 μg of Bcl-2Δ21, respectively. 
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If not used immediately, purified Bcl-2Δ21 was stored with 0.1 mM PMSF at 
-20°C, the best storage conditions to prevent proteolytic degradation of Bcl-2Δ21 as 
identified from the results (data not shown) of the experiment explained in section 
2.2.1-c. 
 
2.3.2: Optimization of BPM labeling reaction conditions. 
(a) Optimum reaction time:   
The Bcl-2Δ21 sample which was not incubated with BPM prior to the reaction 
with ThiGlo1 has more free cysteines and yields more ThioGlo1-cysteine adducts and 
hence more fluorescence (Figure 2.5, sample 1). The two samples incubated with 
BPM have fewer free cysteines to react with ThiGlo1 and produce fewer adducts and 
less fluorescence (Figure 2.5, samples 2 and 3). Even though less fluorescence was 
expected for the sample reacted with BPM for 1 h (Figure 2.5, sample 3) compared to 
the sample incubated with BPM only for 30 min (Figure 2.5, sample 2), both showed 
the same fluorescence intensity. This reveals that the 30 min incubation with BPM is 
sufficient to produce the maximum amount of BPM labeled Bcl-2Δ21. 
 
(b) Effect of the redox status of Bcl-2Δ2 cysteine:   
Since BPM is a thiol reactive cross-linking reagent, the redox status of the 
cysteine affects the efficiency of the BPM labeling reaction.  If the only cysteine 
residue of Bcl-2Δ2, Cys158, is oxidized during protein purification steps it would 
result in a lower yield of BPM-Bcl-2Δ2. Fluorescence measurement of ThioGlo1-
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cysteine adducts of samples without and with DTT (dithiothreitol) treatment does not 
show a significant difference (Figure 2.6, samples 1 and 2, respectively). This reveals 
that the purified Bcl-2Δ2 contains no/very little oxidized cysteines and almost all the 
cysteines in the sample are available for the reaction with BPM. On the other hand, 
the slightly higher fluorescence of DTT-treated sample could be due to the reaction of 
ThioGlo1 with excess DTT even after overnight dialysis (Figure 2.6, sample 2). 
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FIGURE 2.5: Optimum reaction time 
for BPM labeling of Bcl-2Δ21 as 
determined by ThioGlo1 labeling of 
free cysteine residues: (1), sample 
which was not reacted with BPM prior 
to the addition of ThioGlo1; (2) and 
(3), samples which reacted with BPM 
for 30 min and 1 h, respectively,  prior 
to the addition of ThioGlo1. 
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FIGURE 2.6: Redox status of cysteine 
of Bcl-2Δ21 as determined by 
ThioGlo1 labeling of free cysteine 
residues: (1), sample was not treated 
with DTT; (2), sample was treated with 
DTT prior to the addition of ThioGlo1. 
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(c) Effect of native and denatured Bcl-2Δ21: 
As described in section 2.3.2-a, when ThioGlo1 is added to Bcl-2Δ21 which 
has been reacted with BPM, there should be no free cysteines available for adduct 
formation with ThioGlo1. Therefore the comparison of fluorescence intensity of this 
sample (“Bcl-2Δ21→BPM→ThioGlo1”), with that of Bcl-2Δ21 which is directly 
reacted with ThioGlo1 (“Bcl-2Δ21→ ThioGlo1”)   should reveal the amount of BPM-
Bcl-2Δ2 produced. As indicated by these two samples prepared using native Bcl-
2Δ21, less than 10% of the BPM-Bcl-2Δ2 appears to have formed (compare the 
difference between 1 and 2 in Figure 2.7). 
Based on the NMR structure of Bcl-2 (27), the only cysteine, Cys158, of Bcl-
2Δ21 is buried in the interior of the molecule. Therefore the BPM labeling reaction 
was performed under denaturing conditions. The same two samples (“Bcl-
2Δ21→ThioGlo1” and “Bcl-2Δ21→BPM→ThioGlo1”) were prepared in the 
presence of 2% SDS, a strong protein denaturing agent and measured florescence 
(Figure 2.7, samples 3 and 4 respectively). Comparison of these two samples shows a 
BPM-Bcl-2Δ2 yield of about 65% under denaturing conditions. Samples 5 and 6 in 
Figure 2.7 are the two controls indicating the background fluorescence. The control 
sample 5 contains both BPM and ThioGlo1 but lacks Bcl-2Δ21 whereas sample 6 
contains only ThioGlo1.  
Above results confirm that the cysteine residue in Bcl-2Δ2 is not well exposed 
in the native molecule. Upon denaturation the residue becomes exposed yielding 
more BPM-Bcl-2Δ2. However, since SDS is a very strong denaturing agent it could 
 57
drastically change the native conformation of Bcl-2Δ2, necessary for the interaction 
with SERCA. Attempts to use mild denaturing agents such as NP-40 and CHAPS did 
not increase the BPM labeling efficiency (data not shown). Therefore the lowest 
effective SDS concentration which yields a reasonable amount of BPM-Bcl-2Δ2 was 
determined. Approximately 50% of BPM-Bcl-2Δ2 could be achieved in the presence 
of 0.05% SDS (data not shown) and BPM-Bcl-2Δ2 for photo cross-linking 
experiments was prepared in the presence of 0.05% SDS. This SDS concentration is 
enough for facilitating the reaction between BPM and Cys158 of Bcl-2Δ2 and can be 
dialyzed out before the cross-linking reaction.  
 
 
 
 
 
 
 
 
 
 
 
FIGURE 2.7: Comparison of native and denatured Bcl-2Δ21 in BPM labeling, as 
determined by ThioGlo1 labeling of free cysteine residues: (1) and (3), Bcl-
2Δ21→ThioGlo1; (2) and (4), Bcl-2Δ21→BPM→ThioGlo1; (5), BPM/ThioGlo1 
alone; (6), ThioGlo1 alone; (●), samples without 2% SDS; (●), samples with 2% 
SDS.  
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(d) Comparison of Bcl-2Δ2 and His6-Bcl-2Δ17 in cysteine derivatization: 
His6-Bcl-2Δ17 in the native form (Figure 2.8, 2-●) is slightly more efficient 
compared to native Bcl-2Δ2 (Figure 2.8, 1-●) in cysteine derivatization as revealed 
by fluorescence measurement of ThioGlo1-cysteine adducts. The hexahistidine tag of 
His6-Bcl-2Δ17 might be affecting the conformation of the molecule thus making 
Cys158 more exposed and available for derivatization. The two proteins under 
denaturing conditions also show the same pattern in cysteine derivatization (Figure 
2.8, 1and 2-●). However the differences in fluorescence measurements of the two 
proteins might be within experimental error. The measurements were not replicated in 
this experiment due to lack of sufficient proteins and therefore no error bars are 
available.  Over all, the two proteins are comparable in cysteine derivatization ability. 
 
 
 
 
 
 
 
 
FIGURE 2.8: Comparison of Bcl-2Δ2 and His6-Bcl-2Δ17 in cysteine derivatization, 
as determined by ThioGlo1 labeling of free cysteine residues: (1), samples of Bcl-
2Δ21; (2), samples of His6-Bcl-2Δ17; (●) samples without 0. 2% SDS; (●) samples 
with 0.2% SDS.  
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2.3.3: Characterization of BPM labeling reaction sample. 
(a) RP-HPLC separation of BPM labeling reaction mixture: 
  Figure 2.9 shows the chromatograms of BPM labeling reaction samples 
recorded at 280 nm for protein detection. When a sample of Bcl-2Δ21 which was not 
subjected to BPM labeling, was run through the RP-HPLC column, Bcl-2Δ21 eluted 
at 58 min (blue line). The peak at 62 min might be due to proteolytic and/or 
hydrolytic degradation product of Bcl-2Δ21.  When the BPM labeling reaction 
mixture is subjected to RP-HPLC, in addition to the Bcl-2Δ21 peak, additional peaks 
should appear for BPM-Bcl-2Δ21 and also for left over BPM, if any after dialysis.  
As expected, additional peaks were seen eluting at 43 min and at 50 min (red line).  
 
 
FIGURE 2.9: Determination of BPM-Bcl-2Δ21 using RP-HPLC separation of the 
reaction mixture; Chromatograms recorded at 280 nm: (), Bcl-2Δ21 sample 
before BPM labeling; (), Bcl-2Δ21 sample after BPM labeling.  
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According to the chromatograms in Figure 2.10 which were recorded at 260 
nm, the maximum absorbance of BPM-thiol adducts, the peak eluting at 50 min 
showed an increase in absorbance and hence it could be the peak of BPM-Bcl-2Δ21. 
The peak at 43 min could be postulated as unreacted BPM. Absorbance of unlabeled 
Bcl-2Δ21 at 260 nm (Figure 2.10, peak at 58 min) is probably due to the tryptophan 
residues in the molecule.  
 
 
FIGURE 2.10: Determination of BPM-Bcl-2Δ21 using RP-HPLC separation of the 
reaction mixture; Chromatograms recorded at 260 nm: (), Bcl-2Δ21 sample 
before BPM labeling; (), Bcl-2Δ21 sample after BPM labeling.  
 
In order to further verify the identity of these two peaks at 43 min and 50 min, 
the BPM labeling reaction sample was spiked with increasing concentrations of BPM 
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shown in Figure 2.11. The chromatogram in black is for Bcl-2Δ21 which was not 
subjected to BPM labeling. Materials eluted in between 25-32 min could probably be 
some impurities trapped in the column. BPM labeling reaction samples spiked with 
25 μM and 40 μM BPM are indicated in blue and red, respectively. The absorbance 
intensity of the peak at 43 min was clearly increased with 40 μM BPM verifying that 
the material eluting at 43 min is BPM and hence the peak at 50 min is  BPM-Bcl-
2Δ21. Over all these RP-HPLC data indicate the success of the BPM labeling of Bcl-
2Δ21, yet do not confirm the presence of BPM-Bcl-2Δ21 in the reaction mixture. 
Mass spectrometry was utilized to confirm the presence of BPM-Bcl-2Δ21 in the 
mixture (see below). 
 
FIGURE 2.11: RP-HPLC separation of BPM labeling reaction mixture after BPM 
spiking; Chromatograms recorded at 260 nm: Bcl-2Δ21sample before BPM 
labeling (), BPM labeling reaction samples spiked with 25μM () and 40μM () 
BPM are shown.  
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(b) Mass spectrometric analysis of BPM labeling reaction mixture: 
Analysis of the BPM labeling reaction mixture by ESI-FTICR-MS, after in-
gel tryptic digestion, reveals the presence of +3-ly charged Bcl-2Δ21 peptide (m/z 
767.0187) labeled with the hydrolyzed form of BPM. The associated mass error of 
this peptide ion, 8.2 ppm, is below the accepted maximum error (10 ppm) of FTICR-
MS. The MS/MS spectrum of this peptide is shown in Figure 2.12. Both singly and 
doubly charged y7 and b12 ions were found, confirming the presence of derivatized 
Cys158 and these ions are circled in the spectrum.   
 
 
FIGURE 2.12: MS/MS spectrum of BPM labeled peptide of Bcl-2Δ21: Sequence of 
the peptide is shown above the spectrum; y and b ions are labeled in blue and red 
respectively; Internal fragment ions and neutral losses are indicated in pink; y7 and 
b12 ions which include the cysteine labeled with hydrolyzed BPM are circled.  
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(c) Effect of BPM-Bcl-2Δ21 on Ca2+-ATPase activity of SERCA: 
When the interface of interacting proteins is identified through cross-linking, 
the site of the cross-linking reagent is a key factor. If it is too close to the interface or 
at a site directly involved in the interaction, it might block the proteins interacting 
with each other. In the case of Bcl-2Δ21 and SERCA interactions, the photo cross-
linking reagent, BPM is attached to Cys158 of Bcl-2Δ21. This BPM labeled Bcl-
2Δ21 might fail to interact with and inactivate SERCA. Dremina et al. (23) have 
previously shown that the modification of Cys158 of Bcl-2Δ21 does not have any 
effect on the inhibition of SERCA activity, as determined using carboxymethylated 
and also peroxynitrite-treated Bcl-2Δ21. In order to confirm that the labeling of 
Cys158 with BPM is also not affecting the inhibition of SERCA, the Ca2+-ATPase 
activity assay was utilized.  
Sample 1 of Figure 2.13 shows the Ca2+-ATPase activity of the SR in STE 
buffer. The two activity values of this sample before and after 3 h of incubation are 
almost the same. The SR sample incubated with BPM treated Bcl-2Δ21 shows a 
significant reduction of activity compared to the activity before the incubation (Figure 
2.13, Sample 2), confirming that BPM treatment does not affect the inhibition of 
SERCA by Bcl-2Δ21. The activity of this SR sample, measured right after mixing 
with BPM treated Bcl-2Δ21 and before the incubation shows reduced activity. 
Therefore the few minutes taken for the first measurement of activity should be long 
enough to inactivate some of the SERCA in the sample. The third sample (Sample 3 
in Figure 2.13) shows activity values comparable to those of Sample 1. This proves 
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that the reduced activity in Sample 2 after 3 h of incubation is not due to the effect of  
left over SDS in the buffer but is due to  the BPM-Bcl-2Δ21. However, the BPM 
labeling reaction conditions used yield only about 50% of BPM-Bcl-2Δ21 and hence 
the reduction in activity could result from unlabeled  Bcl-2Δ21 in the sample. In a 
separate experiment, two Bcl-2Δ21 samples with and without BPM treatment were 
compared for their ability to reduce the Ca2+-ATPase activity of the SR. Both samples 
could successfully reduce the activity (data not shown) further confirming that the 
BPM treatment does not affect the inhibition of SERCA by Bcl-2Δ21. 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 2.13: Effect of   BPM treated Bcl-2Δ21 on Ca2+-ATPase activity of 
SERCA: (1), SR in STE buffer; (2), SR mixed with BPM-Bcl-2Δ21 in STE buffer; 
(3), SR in the STE buffer which was subjected to BPM labeling reaction conditions; 
(●) before   incubation at 37 °C;  (●) after   incubation at 37 °C. 
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2.3.4: Photo cross-linking of Bcl-2Δ21 with SERCA. 
In photo cross-linking of Bcl-2Δ21with SERCA, the molar ratio of the two 
proteins and the incubation time of Bcl-2Δ21/SR mixture prior to UV irradiation, 
were critical parameters for the formation of cross-linked products. Out of the 
different molar ratios examined, cross-linked products were clearly seen, in the 
western blot with Bcl-2Δ21 antibody, when 2:1 (Bcl-2Δ21: SERCA) ratio was used. 
Complete inactivation of SERCA has been reported previously, after 2 hours of co-
incubation of the two proteins with this ratio (23, 25). With only 15 min of co-
incubation of Bcl-2Δ21 and SR, clear cross-linked bands appeared in the western 
blot. The prolonged incubation times did not increase the intensity of the cross-linked 
bands but smeared lanes in the western blots (data not shown). The results of the 
photo cross-linking experiment completed with 2:1 (Bcl-2Δ21: SERCA) molar ratio 
and 15 min of co-incubation are explained below. 
The Figure 2.14 shows the western blots of photo cross-linked samples. The 
apparent molecular weights of SERCA and Bcl-2Δ21 are ~110 kDa and 25 kDa, 
respectively. Therefore the cross-linked products should appear at 135 kDa and/or 
160 kDa if the molar ratio is 1:1 and 2:1 (Bcl-2Δ21: SERCA), respectively. As 
predicted, two bands appear at 135 kDa and 160 kDa, with the sample containing 
both BPM treated Bcl-2Δ21and SR (Bcl-2Δ21/BPM/SR) in the western blot of the 
Bcl-2 antibody (Figure 2.14-a, lane 3). The intensities of these cross-linked bands are 
significantly lower compared to the bands of monomer and the dimer of Bcl-2Δ21. 
This is acceptable if the interaction is transient as reported previously by Dremina et 
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al. (23, 25). As revealed by the relatively lower intensity of the band at 160 kDa 
compared to that of the 135 kDa band, the 1:1 ratio (Bcl-2Δ21: SERCA) is more 
favorable. 
  Importantly, the control sample of Bcl-2Δ21/BPM without SR shows only 
the monomer and the dimer of Bcl-2Δ21, but no higher oligomers (compare lanes 2 
and 3 of Figure 2.14-a). Therefore the two bands seen above 100 kDa with the Bcl-
2Δ21/BPM/SR sample are probably due to cross-linking of Bcl-2Δ21 with SERCA. 
However, it is possible that some other protein/proteins in the SR, which can interact 
with Bcl-2Δ21, produce bands with identical molecular weights. This is discussed in 
a later section. 
A significant amount of homodimer of Bcl-2Δ21 is seen in the western blot. It 
is already known that the homodimerization of Bcl-2 involves two distinct surfaces of 
Bcl-2, the acceptor and donor surfaces. The Cys158 of Bcl-2Δ21 is located in BH1, 
one of the domains in the acceptor surface (28). Therefore, the cross-linking reagent 
attached at Cys158 in Bcl-2Δ21 can easily form a covalent bond with the other Bcl-
2Δ21 molecule in the dimer. It is interesting to see more homodimers of Bcl-2Δ21 in 
the presence of SR (compare 50 kDa band in lanes 2 and 3 of Figure 2.14-a ). The SR 
vesicle membrane might be facilitating the homodimerization of Bcl-2Δ21. The band 
at 160 kDa could probably be due to the interaction of the homodimer of Bcl-2Δ21 
with a SERCA molecule and the Cys158, hence the BH1 domain of the second 
molecule of Bcl-2Δ21 in the dimer should be involved in the interactions with 
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SERCA. The bands seen between 25 kDa and 50 kDa should be the degradation 
products of the dimer of Bcl-2Δ21.  
 
 
FIGURE 2.14: Photo cross-linking of Bcl-2Δ21 with SERCA: (a) Bcl-2 antibody 
WB of cross-linked samples; (b) SERCA antibody WB of cross-linked samples; (Bcl-
2Δ21/BPM), sample containing BPM treated Bcl-2Δ21 alone; (Bcl-2Δ21/BPM/SR), 
sample containing both BPM treated Bcl-2Δ21 and SR; (SR/BPM), sample 
containing SR in the STE buffer which was subjected to BPM labeling reaction 
conditions; (SR), a fraction of purified SR loaded in the gel as the control for the WB. 
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The SERCA antibody WB of the cross-linking experimental samples is shown 
in the Figure 2.14-b. Unexpectedly, the result of this WB is not consistent with that of 
the Bcl-2 antibody WB. The photo cross-linked reaction sample, Bcl-2Δ21/BPM/SR, 
(Figure 2.14-b, lane 3) and also the control sample without Bcl-2Δ21, SR/BPM, 
(Figure 2.14-b, lane 2) show identical results in the WB.  
A fraction of purified SR vesicles was loaded on the gel (Figure 2.14-b, lane 
4) as a control for the WB.  Compared to this lane 4, not only the photo cross-linking 
reaction sample, Bcl-2Δ21/BPM/SR, but also the control sample, SR/BPM, show a 
band corresponding to the dimer of SERCA-Bcl-2Δ21 at 135 kDa, where the cross-
linked bands are seen in the WB with the Bcl-2 antibody. It should be mentioned here 
that the purified SR vesicles contain a very small fraction of co-purified Bcl-2 and it 
can cause the band in the SR/BPM control sample. If that is the case, the intensity of 
the band of Bcl-2Δ21/BPM/SR sample should be higher than that of the SR/BPM 
control sample because the Bcl-2Δ21/BPM/SR sample contains a relatively huge 
amount of Bcl-2Δ21 and therefore more cross-linked SERCA-Bcl-2Δ21. However the 
intensities of the bands of the two samples are the same. On the other hand the same 
SR/BPM control sample in the WB of Bcl-2 antibody does not show any band in the 
same region (Figure 2.14-a, lane 4). For these reasons the bands in the two samples 
are probably not the cross-linked SERCA and Bcl-2Δ21/Bcl-2.  
The control sample was prepared by dissolving SR in the STE buffer, which 
was subjected to all the BPM labeling reaction steps but without Bcl-2Δ21 and 
therefore it should indicate the effect of BPM left in the buffer, if any, after dialysis. 
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Therefore the bands seen above the SERCA band (110 kDa), with both samples, are 
probably caused by the BPM left in the sample, even after 4 hours of dialysis. There 
are 24 cysteine residues in SERCA and any left over BPM can label some of these 
cysteines. The BPM labeled SERCA should appear above 110 kDa in the WB.  
Furthermore, only a pale smear is seen corresponding to the trimer of   
SERCA-2Bcl-2Δ21 (160 kDa) and the intensity of this smear is also the same in both 
samples.  These results suggest that WB with SERCA antibody does not indicate the 
presence of SERCA/Bcl-2Δ21 cross-linked products. The monoclonal SERCA 
antibody used in our studies recognizes an epitope located between Ala506 and the C-
terminal of the molecule. If the SERCA interface for Bcl-2Δ21 is located within this 
region of the molecule, antibody recognition might be affected and the results seen in 
the WB of SERCA antibody can be accepted. In fact which is the case as revealed by 
mass spectrometric data (see 2.3.6).  
Also if there are some other proteins in the SR which are comparable with 
Bcl-2Δ21 in size and can interact with SERCA , the  BPM labeled SERCA can cross-
link with those proteins causing bands in the same region as the cross-linked products 
of SERCA and Bcl-2Δ21. This is addressed under “Other possible SR proteins 
associated with Bcl-2 or SERCA”. 
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2.3.5: Photo cross-linking of His6-Bcl-2Δ17 with SERCA. 
In photo cross-linking reactions with His6-Bcl-2Δ17 samples were subjected 
to Ni2+ affinity purification. This procedure helps to purify cross-linked products of 
His6-Bcl-2Δ17 from the reaction mixture thereby making the sample less complex 
and also enriched with cross-linked products.  
 
 
 
FIGURE 2.15: Photo cross-linking of His6-Bcl-2Δ17 with SERCA: Bcl-2 antibody 
western blot of the fractions of His6-Bcl-2Δ17/BPM/SR cross-linking reaction sample 
eluted from the Ni2+ column with different concentrations of imidazole (Im). The last 
lane is 0.1µg of His6-Bcl-2Δ17 as a control for the western blot.  
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The fractions of His6-Bcl-2Δ17/BPM/SR sample in the WB of Bcl-2 antibody 
show His6-Bcl-2Δ17 in the 500 mM Im fraction (Figure 2.15). The same 500 mM 
fraction shows monomer, dimer and also probably a trimer of His6-Bcl-2Δ17. 
Consistent with the results seen for the cross-linking reaction of Bcl-2Δ21, two bands 
(marked with a circle) are seen corresponding to the cross-linked products of His6-
Bcl-2Δ17 with SERCA with the sizes of 135 kDa and 160 kDa. His6-Bcl-2Δ17/BPM 
control sample fractions did not show any band above 100 kDa (data not shown), 
confirming that these two bands are not due to oligomerization of BPM-His6-Bcl-
2Δ17.  
Figures 2.16-a and b are SERCA antibody western blots of the BPM-His6-Bcl-
2Δ17/SR sample and the SR/BPM control sample, respectively. The comparison of 
the fractions of His6-Bcl-2Δ17/BPM/SR cross-linking reaction sample (Figure 2.16-a) 
reveals that SERCA is also trapped in the column and is eluted with high 
concentrations of Im. This could be due to the association of SERCA with His6-Bcl-
2Δ17. However, since SERCA is seen in the higher Im fractions of the SR/BPM 
control sample, SERCA itself has some affinity for the Ni2+ ions.   
The 100 mM Im fraction of the Bcl-2Δ17/BPM/SR sample shows a band at 
~135 kDa which is not detected in the western blot with Bcl-2 antibody (compare the 
100 mM Imidazole fraction in Figure 2.15 with that of Figure 2.16-a). This confirms 
the presence of some other product/products of SERCA of the same size as the cross-
linked SERCA-His6-Bcl-2Δ17 dimer. Since this band is seen only with Bcl- 
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FIGURE 2.16: Photo cross-linking of His6-Bcl-2Δ17 with SERCA: SERCA 
antibody western blots of the fractions of the His6-Bcl-2Δ17/BPM/SR cross-linking 
reaction sample (a) and the SR/BPM control sample (b) eluted from the Ni2+ column 
with different concentrations of imidazole (Im). The last lane is a fraction of purified 
SR vesicles as a control for the western blot. The lanes and the regions of the two 
western blots that should be compared with the western blot in Figure 2.15 are 
marked with dashed lines. 
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2Δ17/BPM/SR sample and not with the SR/BPM control, formation of these other 
product/products of SERCA should be facilitated by the presence of His6-Bcl-2Δ17.   
Two bands that can be considered as cross-linked products of His6-Bcl-2Δ17  
were seen in the fraction of 500 mM Im with the western blot of Bcl-2 antibody 
(Figure 2.15). When the same fraction is considered in the western blots of SERCA 
antibody, the His6-Bcl-2Δ17/BPM/SR sample indicates a band at ~135 kDa with a 
higher intensity compared to the SR/BPM control sample (compare the circled 
regions of the western blots in Figure 2.16). This band could rather be 
product/products of SERCA carrying over to the fraction of 500 mM Im other than 
the cross-linked dimer of SERCA-His6-Bcl-2Δ17. In addition the western blots of 
SERCA antibody do not reveal a band at 160 kDa corresponding to the trimer of 
SERCA-2His6-Bcl-2Δ17. These observations with the western blots of SERCA 
antibody further supports the assumption that after binding with Bcl-2, SERCA is not 
recognized by the antibody. 
 
2.3.6: Chemical cross-linking of Bcl-2 Δ21 with SERCA.  
In addition to the photo cross-linking using BPM, four heterobifunctional 
chemical cross-linkers, BMPS, MBS, SMCC and SMPH, with different spacer 
lengths were used to cross-link Bcl-2Δ21 with SERCA. The two functionalities of the 
cross-linkers are the amine reactive NHS-ester and the sulfhydryl reactive maleimide 
group. Since the Bcl-2Δ21 purification buffer, STE, consists of Tris which contains 
primary amines, it was exchanged with the PBS buffer before the cross-linking 
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reaction, to prevent the reaction of the cross-linker with the Tris.  The cross-linking 
experiments were completed using the same two-step procedure used in photo cross-
linking. In the first step the cross-linker is attached to one of the proteins and the 
excess reagent is removed. The addition of the second protein during the second step 
results in cross-linked products. Experiments were completed starting with either Bcl-
2Δ21 (Bcl-2Δ21-Linker → SR) or SR (SR-Linker → Bcl-2Δ21). The reaction started 
with Bcl-2Δ21 (Bcl-2Δ21-Linker → SR) did not show any cross-linked products 
(data not shown). The modification of Bcl-2Δ21 by the cross-linker at multiple sites 
might have drastically changed the conformation of Bcl-2Δ21 necessary for the 
association with SERCA. On the other hand, the reaction started with SR (SR-Linker 
→ Bcl-2Δ21) generated clear western blots and are explained below.  
When the linker is added to SR, all the SR proteins including SERCA are 
labeled with the linker. Upon mixing with Bcl-2Δ21, linker-attached SERCA and also 
the other proteins capable of interacting with Bcl-2Δ21, make cross-linked products. 
The western blot with Bcl-2 antibody clearly shows the products of Bcl-2Δ21 above 
100 kDa (Figure 2.17, lanes 3-6). The possible SERCA/Bcl-2Δ21 products should 
also be among these bands. The absence of bands above 100 kDa with the control 
samples of cross-linker/Bcl-2Δ21 (Figure 2.17, lanes 7-10) and also of Bcl-2Δ21/SR 
(lane 2) confirms that the bands seen with the samples of SR/cross-linker/Bcl-2Δ21 
are not oligomers but cross-linked products of Bcl-2Δ21 with the proteins of SR.  
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FIGURE 2.17: Chemical cross-linking of Bcl-2Δ21 with SERCA: Bcl-2 antibody 
western blot of the chemical cross-linking reaction samples of SR/cross-linker/Bcl-
2Δ21 and cross-linker/ Bcl-2Δ21. The cross-linked products of Bcl-2Δ21 seen with 
the samples of SR/cross-linker/Bcl-2Δ21 are boxed. Bcl-2Δ21/SR is the control 
sample without any cross-linker. 
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linkers, BMPS, SMCC and SMPH, show the same yields (compare lanes 3-6 in 
Figure 2.17). However since all the bands above 75kDa of SR/MBS/Bcl-2Δ21 (lane 
4) are less intense, this could probably be the result of some structural constraints 
associated with MBS in cross-linking. Since BMPS, SMCC and SMPH show the 
same efficiency, the distance between the interface/interfaces of Bcl-2Δ21/SERCA 
complex can range from ~6-14Å. 
In order to identify the cross-linked products of SERCA, the chemical cross-
linking reaction samples were probed with SERCA antibody (Figure 2.18). As seen in 
the western blot, almost all SERCA in the two sets of samples of SR/cross-linker/Bcl-
2Δ21 and SR/cross-linker is present as higher oligomers of >250 kDa. Two cross-
linked products of SERCA are seen with the samples of SR/cross-linker/Bcl-2Δ21 
(Figure 2.18, lanes 3-6) specifically with SMCC and BMPS. However the same bands 
are seen even in the absence of Bcl-2Δ21 as seen with the control samples of 
SR/cross-linker (Figure 2.18, lanes 7-10), which did not show any band with Bcl-2 
antibody (data not shown). Nevertheless the pattern of the intensities of these bands is 
not comparable to those with Bcl-2 antibody. Therefore these products cannot be of 
SERCA/Bcl-2Δ21 and the previously made assumption, after binding with Bcl-2, 
SERCA is not recognized by the antibody, should be emphasized here too. Since the 
intensities of the bands are higher in the samples of SR/cross-linker/Bcl-2Δ21, cross-
linking of SERCA with other SR proteins is somehow facilitated by the presence of 
Bcl-2Δ21.  
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FIGURE 2.18: Chemical cross-linking of Bcl-2Δ21 with SERCA: SERCA antibody 
western blot of the chemical cross-linking reaction samples of SR/cross-linker/Bcl-
2Δ21 and the control samples of SR/cross-linker and Bcl-2Δ21/SR. The region of the 
blot indicating cross-linked products is boxed. 
 
  
2.3.7: Mass spectrometric analysis of photo cross-linked SERCA/Bcl-2Δ21. 
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samples in the order of SR/BPM and Bcl-2Δ21/SR, were run in the instrument first 
followed by the digests of Bcl-2Δ21/BPM/SR sample, in order to prevent any carry 
over effect. The amino acid coverages of SERCA were 45%, 45% and 39% for the 
Bcl-2Δ21/BPM/SR, Bcl-2Δ21/SR and SR/BPM, respectively. The appearance of 
SERCA in the gel bands of SR/BPM and Bcl-2Δ21/SR control samples is acceptable 
since SERCA was seen at 160 kDa of the control samples in the western blots of 
SERCA antibody. Importantly, Bcl-2Δ21 peptides showed up in the digests of the 
Bcl-2Δ21/BPM/SR sample and also of the Bcl-2Δ21/SR control sample with the 
amino acid coverages of 50% and 55%, respectively. When this Bcl-2Δ21/SR control 
sample was subjected to western blot analysis with Bcl-2 antibody, Bcl-2Δ21 was 
seen at 160 kDa with relatively lower intensity compared to the band of Bcl-
2Δ21/BPM/SR sample (see Figure 2.25). Therefore the appearance of Bcl-2Δ21 
peptides in this Bcl-2Δ21/SR control sample is acceptable.  
In another trial the gel bands corresponding to both 160 kDa and 135 kDa 
bands, identified with Bcl-2 antibody, were cut out from Bcl-2Δ21/BPM/SR and the 
SR/BPM control sample and analyzed by MS after in-gel tryptic digestion. As in the 
first trial, SERCA showed up in the SR/BPM control sample with the amino acid 
coverages of 51% and 48% in 135 kDa and 160 kDa gel bands, respectively. The 
coverages of SERCA of Bcl-2Δ21/BPM/SR sample were 42% and 49% in 135 kDa 
and 160 kDa gel bands, respectively. However Bcl-2Δ21, with amino acid coverage 
of 13%, was seen only in the 135 kDa band but not in the 160 kDa band  probably 
due to the suppression of relatively lower abundant Bcl-2Δ21 peptides by the highly 
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abundant peptides generated from the proteins of SR including SERCA present in the 
gel band. The results of the two mass spectrometric trials explained above are 
summarized in the following table. 
 
TABLE 2.1: Summary of mass spectrometric results: The amino acid coverages of 
Bcl-2Δ21 and SERCA in 135 kDa and 160 kDa gel bands of  Bcl-2Δ21/BPM/SR, 
Bcl-2Δ21/SR and SR/BPM samples are shown. † Cross-linked SERCA-Bcl-2Δ21 
dipeptide was identified in this sample. 
 
Bcl-2Δ21 SERCA Bcl-2Δ21 SERCA Bcl-2Δ21 SERCA
Trial 1 160 kDa – 37% 50% † 45% 55% 45%
Trial 2 135 kDa – 51% 13% 49%
160 kDa – 48% – 42%
SR/BPM Bcl-2Δ21/BPM/SR Bcl-2Δ21/SR
  
 
 
The successful identification of the cross-linked peptides using mass 
spectrometry depends on the concentration of the cross-linked material in the sample 
to be analyzed. In the case of SERCA and Bcl-2Δ21, the yield of cross-linked 
SERCA-Bcl-2Δ21 is much lower as revealed by western blotting with Bcl-2 
antibody. Therefore some separation techniques should be involved in order to enrich 
the sample with the low-abundance cross-linked products.  Using 1D SDS-PAGE, the 
complex mixture of Bcl-2Δ21/BPM/SR cross-linking reaction sample can be 
separated based on the apparent molecular weights. Even though the gel bands of 
interest are now enriched with the cross-linked products, the in-gel digest is a 
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complex mixture of peptides of SERCA and Bcl-2Δ21itself and also of some other 
SR proteins of the same molecular weight as the cross-linked products. Therefore the 
concentration of low-abundance cross-linked peptide/peptides would still be outside 
the dynamic range of the mass spectrometer. Also the signal for the cross-linked 
product can be easily suppressed by highly abundant peptides. On-line RP-HPLC 
separation, associated with LC/MS methodologies is extremely helpful in analyzing 
such low abundant cross-linked peptides.  
The MS data mentioned above were further analyzed for the possible cross-
linked SERCA-Bcl-2Δ21 dipeptides. This was done manually by comparing the 
theoretical masses of SERCA-Bcl-2Δ21 dipeptides with the experimentally found 
masses. The SERCA-Bcl-2Δ21 dipeptide formed by cross-linking of the Bcl-2Δ21 
peptide, 147IVAFFEFGGVMC(BPM)VESVNR164 with the SERCA peptide, 
568DTPPKR573 was identified in the 160 kDa band of the Bcl-2Δ21/BPM/SR sample 
in the first MS trial (see Table 2.1).  
Figures 2.19 and 2.20 show MS1 of [M+4H]+4 and [M+3H]+3 ions, 
respectively, of the identified dipeptide. The spacing between the isotopic peaks of 
[M+4H]+4 and [M+3H]+3 ions are 1/4 and 1/3 respectively, confirming the charge 
states. The excellent peak resolution that can be achieved with FTICR-MS is helpful 
in identifying the isotopic peak envelopes of the two ions. The calculated m/z values 
of the two ions are 749.1099 ([M+4H]+4) and 998.4798 ([M+3H]+3), with associated  
errors of 24.2 ppm and 33.3 ppm, respectively.  Even though these error values are 
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higher than the maximum error level of masses detected by FTICR-MS, still those are 
acceptable for a low abundant cross-linked dipeptide.  
These two ions were found only in the sample of Bcl-2Δ21/BPM/SR and 
when the two control samples were searched, no peaks were found with the same m/z 
and isotopic distribution. Figure 2.21 shows the intensities of the five isotopic peaks 
of [M+4H]+4 ion of Bcl-2Δ21/BPM/SR sample, relative to the intensities of the same 
m/z values found in the same chromatographic time window of the two control 
samples. This clearly indicates that [M+4H]+4  ion is present only in the Bcl-
2Δ21/BPM/SR sample but not in the two control samples.  
Furthermore, the theoretical masses of +3ly and +4ly charged peptide ions 
generated from SERCA and  Bcl-2Δ21 itself  and also from the  intramolecularly 
cross-linked peptides of Bcl-2Δ21, were searched and no m/z was found with the 
same masses reported here. Since purified SR vesicles were used in the experiments 
as the source of SERCA, all the samples contain the other proteins found in the SR 
and hence the digests contain the peptides of these other SR proteins. The theoretical 
masses of these other SR proteins, showed up only in the Bcl-2Δ21/BPM/SR sample 
but not in the two control samples, were also searched and no matching ions were 
found. Therefore the identified ions can be confirmed as of the cross-linked SERCA-
Bcl-2Δ21 dipeptide.   
 
 
 
 82
 
 
FIGURE 2.19: Mass Spectrum of [M+4H]+4 of the cross-linked SERCA-Bcl-2Δ21 
dipeptide: The isotopic peak distribution of MS1 of quadruply charged ion is shown. 
The spacing between peaks are shown confirming the +4 charge state. In-set shows 
the cross-linked dipeptide, peptide of SERCA in red and peptide of Bcl-2Δ21 in blue. 
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FIGURE 2.20: Mass Spectrum of [M+3H]+3  of the cross-linked SERCA-Bcl-2Δ21 
dipeptide: The isotopic peak distribution of MS1 of triply charged ion is shown. Four 
peaks belonging to the isotopic envelope are labeled in blue. Spacing between peaks 
are shown confirming the +3 charge state.  
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FIGURE 2.21: Intensities of the isotopic peaks of [M+4H]+4  relative to the control 
samples: () Bcl-2Δ21/BPM/SR; () Bcl-2Δ21/SR; () SR/BPM. 
 
 
  
 
Figure 2.22 shows the 3-D structure of SERCA showing the position of this 
cross-linked SERCA peptide. The identified SERCA peptide, 568DTPPKR573, cross-
linked to Bcl-2Δ21, is located at cytoplasmic ATP binding domain (residues 505-
680). More importantly it is located right next to 560RCLALA565, one of the conserved 
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binding, as measured using NMR spectroscopy (30). Therefore the residue Thr569 
and hence 568DTPPKR573 could be directly involved in ATP binding during the 
catalytic cycle of SERCA. However, there are no mutational studies available to date, 
confirming the importance of this residue in ATP binding of SERCA. 
  
   
FIGURE 2.22: The 3-D structure of SERCA showing the peptide cross-linked to 
Bcl-2Δ21: 568DTPPKR573 peptide of SERCA located in the ATP binding domain is 
circled. The structure of SERCA is from protein data bank (PDB code 1SU4). 
 
 
The Bcl-2Δ21 peptide, 147IVAFFEFGGVMC(BPM)VESVNR164, belongs to 
the BH1 domain which is one of the three domains in the hydrophobic surface groove 
of Bcl-2Δ21 explained in the chapter 1. Therefore this hydrophobic surface groove of 
Bcl-2Δ21 might directly but transiently interact with the ATP binding domain of 
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SERCA thus blocking the cross-talk between ATP binding and phosphorylation 
domains  which is required for  SERCA activity. As reported previously, SERCA-
Bcl-2Δ21 interaction does not change the ATP binding affinity of the domain (23). 
Interaction of Bcl-2Δ21 with the ATP binding domain would not necessarily change 
the affinity of the domain for ATP.  Apart from this ATP binding domain, Bcl-2Δ21 
might interact with other domains of SERCA which are not identified under this 
study. 
In order to identify the exact cross-linking residue within this SERCA peptide, 
MS/MS data of the identified ions are needed. However, MS/MS of the [M+4H]+4 and 
[M+3H]+3  ions could not be found probably because, the ion currents of the two ions, 
m/z 749.1281 and m/z 998.5131,  are considerably lower (5.03E2 and 5.06E2, 
respectively) than the defined threshold (10E6) for MS/MS during the MS run. The 
benzophenone group of the cross-linking reagent, BPM, abstracts a proton from an 
adjacent, geometrically accessible C-H bond upon UV irradiation. When a hetero 
atom such as N or S is next to the alkyl group, this H abstraction by benzophenone is 
more favorable (8). The identified cross-linked SERCA peptide, 568DTPPKR573, 
contains two Prolines (P), a Lysine (K) and an Arginine (R), and all contain alkyl 
groups adjacent to N atoms. Therefore, the exact cross-linking site could be one of 
these residues. The spacer arm length of BPM is within 8-11Å, therefore the distance 
between Cys158 of Bcl-2Δ21and the cross-linked residue in SERCA should be within 
this range.  
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2.3.8: Other possible SR proteins associated with Bcl-2Δ21 or SERCA. 
Purified SR vesicles were used as the source of SERCA in all the cross-
linking experiments. It is possible that Bcl-2Δ21 and also SERCA can interact with 
some other proteins in SR and produce cross-linked products comparable in size to 
the products of SERCA/Bcl-2Δ21. Therefore the digests of 135 kDa and 160 kDa gel 
bands might contain these other products. Searching the mass spectrometric data 
against the mouse/rat data base for the  identification of the proteins in the digests 
revealed some SR proteins which are reasonable in size to be considered as cross-
linked to  Bcl-2Δ21 or SERCA. Suspected Bcl-2Δ21 cross-linked proteins are 
Dihydropyridine-sensitive L-type calcium channel subunits α-2/ δ precursor (125 
kDa, P54290), Sarcalumenin precursor (99 kDa, Q7TQ48) and Glycogen 
phosphorylase, muscle form (97 kDa, P00489). A suspected SERCA cross-linked 
protein found was Mitsugumin-29 (Mg29) (29 kDa, O89104). Mg29 has recently 
been found in the triad-junction of skeletal muscle (31). 
Affinity purified fractions of the photo cross-linking reaction sample of His6-
Bcl-2Δ17/BPM/SR and also the GST-Bcl-2Δ21 binding assay samples were 
subjected to western blot analysis using the antibodies for  the suspected Bcl-2Δ21 
cross-linked proteins, Dihydropyridine-sensitive L-type calcium channel subunits α-
2/ δ precursor, Sarcalumenin precursor and Glycogen phosphorylase, muscle form. 
The three western blots of the photo cross-linked samples did not show any band that 
can be considered as a cross-linked product (data not shown). Also the western blots 
of the GST-Bcl-2Δ21 binding assay samples show that these three proteins do not 
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directly associate with Bcl-2Δ21 (data not shown).  Therefore the presence of these 
three proteins in the digests is probably due to the contamination during manual 
isolation of the gel bands of interest. 
The affinity purified fractions of photo cross-linking reaction sample, His6-
Bcl-2Δ17/BPM/SR, and of the control sample, BPM/SR, were subjected to western 
blot analysis with the antibody for Mg29, the suspected SERCA cross-linked protein. 
No band was seen at 29 kDa for the monomer of Mg29, a band slightly above 100 
kDa was seen instead with the fractions of both His6-Bcl-2Δ17/BPM/SR and 
BPM/SR (Figure 2.23-a,b). This band of Mg29 could be due to associated 
SERCA/Mg29 or an oligomer, probably a tetramer (116 kDa), of Mg29. The western 
blots of SERCA antibody of the same sample fractions reveal the highest amount of 
SERCA in the fraction of 100 mM Im (lane 5 in Figure 2.23-c,d) and the band of 
Mg29 shows the same pattern of intensity as SERCA (compare a, b with c, d), 
indicating direct or indirect association of this product of Mg29 with SERCA. 
Interestingly the intensities of the band are significantly higher with the fractions of 
His6-Bcl-2Δ17/BPM/SR (compare a and b in Figure 2.23). Therefore the association 
of SERCA with the product of Mg29 might be facilitated by the presence of His6-Bcl-
2Δ17.  
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FIGURE 2.23: Affinity purified fractions of photo cross-linking reaction samples: 
(a),(b), western blots of Mg29 antibody; (c),(d), western blots of SERCA antibody; 
(a),(c), fractions of the SR/BPM control sample; (b),(d), fractions of the His6-Bcl-
2Δ17/BPM/SR sample.  
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GST-Bcl-2Δ21 binding assay was also utilized to further verify Bcl-2Δ21- 
facilitated association of Mg29 with SERCA. As reported before, SERCA is seen 
with the sample of GST-Bcl-2Δ21/SR (Figure 2.24-a). Interestingly the western blot 
of  Mg29 antibody shows the same band (Figure 2.24-b) previously detected with 
affinity purified fractions of photo cross-linking samples (Figure 2.23-a). As 
mentioned before, this could be postulated as a tetramer of Mg29 or a complex of 
SERCA/Mg29. These results further confirm the association of Mg29 with SERCA 
supported by Bcl-2Δ21. The three proteins might be candidates of a protein complex 
which is involved in controlling SERCA activity. However, more experiments are 
needed to confirm this. 
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FIGURE 2.24: GST-Bcl-2Δ21 binding assay samples: (a) western blot of SERCA 
antibody;  (b) western blot of Mg29 antibody;  GST-Bcl-2Δ21/SR sample shows the 
proteins of SR associated with  GST-Bcl-2Δ21; SR-control sample shows the proteins 
of SR non-specifically bound to glutathione-agarose beads. 
25 
20 
50 
37 
250 
150 
100 
75 
G
ST
-B
cl
-2
Δ
21
/S
R
 
SR
-c
on
tro
l 
SR
 2
µg
 
Mg29 monomer -29kDa 
Mg29 dimer -58kDa 
Mg29 trimer-87kDa 
kDa 
1 3 42 
SERCA/Mg29 or  Mg29 
tetramer-116kDa 
(b) 
G
ST
-B
cl
-2
Δ
21
/S
R
 
SR
-c
on
tro
l 
SR
 0
.2
5µ
g 50 
37 
250 
150 
100 
75 
kDa 1 3 42
SERCA 
(a) 
 92
2.3.9: Comparison of young and old SERCA in photo cross-linking with Bcl-2Δ21. 
Young and old SERCA was compared for the efficiency of cross-linking with 
Bcl-2Δ21, using the SR vesicles purified from tissues of young (5-6 months) and old 
(34 months) rats. Since BPM treated Bcl-2Δ21 in this experiment was allowed to 
interact with SERCA for 45 min (optimum incubation time is 15 min as determined in 
a later experiment), the cross-linking reaction samples, Bcl-2Δ21/BPM/SR(Y) and 
Bcl-2Δ21/ BPM/SR(O), show many non-specific products resulting in rather smeared 
lanes with Bcl-2 antibody (Figure 2.25-a). Yet the western blot clearly indicates the 
difference between young and old SERCA in cross-linking with Bcl-2Δ21. The cross-
linked products of Bcl-2Δ21/SERCA with 1:1 and 1:2 (mol/mol) (SERCA: Bcl-
2Δ21) ratio are seen with both young and old SERCA (Figure 2.25-a).  However, 
relatively less products were seen with old SERCA (compare lanes 2 and 8 in Figure 
2.25-a). As seen with previous experiments, the western blot with SERCA antibody 
does not show results compatible to Bcl-2 antibody (Figure 2.25-b). 
As revealed by this cross-linking experiment, association of Bcl-2Δ21 with 
old SERCA is relatively less efficient. Post translational modifications such as 
phosphorylation, nitration, cause alterations in structure and function of a protein. 
SERCA is reported to accumulate oxidational modifications with aging, resulting in 
reduced activity and conformational changes in the molecule.  These structural and 
functional alterations in SERCA, due to aging, could make the interaction with Bcl-
2Δ21 less efficient. Therefore anti-apoptotic action of Bcl-2Δ21 at the level of ER 
might become less effective with aging. 
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FIGURE 2.25: Young and old SERCA in photo cross-linking with Bcl-2Δ21: (a) 
western blot with Bcl-2 antibody, the regions of the Bcl-2Δ21/SERCA cross-linked 
products with young and old SERCA are boxed; (b) western blot with SERCA 
antibody; Photo cross-linking reaction samples of young and old SERCA are labeled 
as Bcl-2Δ21/BPM/SR(Y) and Bcl-2Δ21/ BPM/SR(O) respectively (lanes 2 and 8).  
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2.4: Conclusions. 
In conclusion, the experiments described in this chapter suggest a direct 
interaction of Bcl-2Δ21 with SERCA. The two proteins can interact with both 1:1 and 
2:1 (Bcl-2Δ21: SERCA) molar ratio. The BH1 domain, therefore the hydrophobic 
surface groove of Bcl-2Δ21 is involved in the interaction. Fulfilling one of the major 
objectives of the work reported in this dissertation, 568DTPPKR573 peptide of ATP 
binding domain of SERCA is identified as the site of SERCA involved in the 
interaction. The trans membrane domain of Bcl-2 is not required for this interaction. 
However, apart from these identified domains, there might be other interacting 
domains of the two proteins which are not identified under the experiments reported 
here. Based on the chemical cross-linking experiments, the distance between the 
interface/interfaces of Bcl-2Δ21/SERCA complex can range from ~6-14Å. 
Mitsugumin-29 (Mg29) could also be involved in this Bcl-2Δ21/SERCA interactions. 
The association of SERCA with Bcl-2Δ21 is affected by aging.  
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Chapter 3: 
Effect of Bcl-2Δ21 mutants on the interaction with SERCA. 
 
3.1 Introduction to the analytical strategies. 
3.1.1: Mutants of Bcl-2Δ21. 
 The in vitro studies of SERCA/Bcl-2 interactions described in Chapter 2 
include photo cross-linking of the BH1 domain of Bcl-2Δ21 with SERCA using 
Benzophenone-4-maleimide (BPM), the cross-linking reagent, attached to Cys158 of 
wild type (WT) Bcl-2Δ21. Since the Cys158 is located in the hydrophobic groove of 
Bcl-2Δ21 (1,2), the labeling with BPM was difficult. To overcome this problem 
“Cys-mutants” of Bcl-2Δ21 were generated. In these Cys-mutants, the highly exposed 
Ser residues, based on the NMR structure of Bcl-2 (1), were substituted with Cys, 
while rather buried Cys158, the only one Cys residue of Bcl-2Δ21, was substituted 
with Ser. In addition to the Cys-mutants, the G145E mutation, which has been 
reported to completely diminish the anti- apoptotic activity of human Bcl-2 (3), was 
also selected for the SERCA/ Bcl-2Δ21 interaction studies. Site-directed mutagenesis 
was utilized to generate the mutants of Bcl-2Δ21, using a synthetic oligonucleotide 
primer(s) which is complementary to the DNA sequence of the protein to be mutated 
but consists of an internal mismatch corresponding to the necessary mutation (4). 
These mutants of Bcl-2Δ21 would be helpful in the identification of the 
domains/residues of Bcl-2Δ21 which are critical for the interaction with SERCA, one 
of the main objectives of the project.  
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3.1.2: Sucrose Density Gradient (SDG) fractionation of SR membranes. 
Sucrose Density Gradient (SDG) fractionation can be used to fractionate 
cellular extracts based on the buoyant densities of the different particles in the 
sample. A gradient of sucrose is prepared in a centrifuge tube containing the sample 
to be fractionated by gently overlaying sucrose solutions of decreasing concentrations 
on top of each other so that the highest concentration is at the bottom of the tube. 
Upon centrifugation, the particles of the sample travel through the gradient and stop 
when their density matches that of the surrounding sucrose. The fractions of the 
gradient are removed carefully and further analyzed (5).  
It has been shown previously, using SDG fractionation of purified SR vesicles 
in the presence and absence of Bcl-2Δ21, that the localization of SERCA in the SR 
membrane and thereby in the sucrose gradient, is changed by Bcl-2Δ21 (6). In this 
study SDG fractionation is used to examine the effect of the mutants of Bcl-2Δ21 to 
induce this translocalization of SERCA.  
 
3.1.3: Ca2+-ATPase activity assay. 
 The Ca2+-ATPase activity assay is used to see the effect of the three mutants 
of Bcl-2Δ21 on the ATP hydrolysis activity of SERCA. The inorganic phosphate (Pi) 
released by the hydrolyzed ATP is colorimetrically measured as a complex of the 
phosphomolybdate-malachite green (7, 8). The complex absorbs at 660 nm and the 
intensity of the complex is proportional to the amount of Pi/hydrolyzed ATP in the 
sample. Both total and basal ATPase activities of the purified SR vesicles were 
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measured and the basal activity is subtracted from the total activity to obtain the Ca2+ 
dependent ATPase activity of the sample. Measured activity using this method is the 
Ca2+ dependent ATPase activity of SERCA since it has been shown before that this 
activity can be completely inhibited by the addition of thapsigargin, a well known 
inhibitor of SERCA (9).   
 
3.1.4: Immunoprecipitation and GST- Bcl-2Δ21 binding assay. 
 Immunoprecipitation and the GST-Bcl-2Δ21 (where GST stands for 
Glutathione-S-Transferase) binding assay are two classical methods used for the 
detection of protein-protein interactions (10-13). The strategy involved is to affinity 
purify a protein/protein complex from a mixture using an antibody or any other 
affinity tag. The basic immunoprecipitation experiment includes the addition of the 
antibody to a mixture of proteins such as a cell lysate followed by the precipitation of 
the protein/protein complex bound to the antibody. Then the protein/protein complex 
is dissociated from the antibody and analyzed. In the experiments reported here, 
monoclonal Bcl-2 antibody is used to immunoprecipitate Bcl-2Δ21 from a mixture of 
Bcl-2Δ21/SR and the precipitated proteins are analyzed for any Bcl-2Δ21 bound 
proteins of the SR. In the GST-Bcl-2Δ21 binding assay, the GST tagged fusion 
protein is used to fish the proteins out of the SR which interact with Bcl-2Δ21. 
Commercially available glutathione-agarose beads can be used to purify Bcl-2Δ21 
bound proteins of SR due to the affinity of GST for glutathione.  
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3.1.5: Photo cross-linking of mutants of Bcl-2Δ21with SERCA. 
 The importance of photo cross-linking in the studies of protein interactions is 
described in Chapter 2 under Section 2.1.1. The photo cross-linking ability of the 
mutants of Bcl-2Δ21 with SERCA was compared using the same photo cross-linking 
reagent BPM, used in the cross-linking experiments of wild type Bcl-2Δ21.  
 
3.2: Materials and methods. 
3.2.1: Site directed mutagenesis of Bcl-2Δ21. 
The mutagenic oligonucleotide primers, 5’-AGG GAC GGG GTG AAC TGG 
GAG AGG ATT GTG GCC TTC TTT GAG-3’, 5’-TTT GAG TTC GGT GGG GTC 
ATG TCA GTG GAG AGC GTC AAC-3’, 5’-AAG TAC ATC CAT TAT AAG 
CTG TGT CAG AGG GGC TAC GAG TGG-3’ and  5’-CTG TAC GGC CCC TGC 
ATG CGG CCT CTG-3’ for G145E, C158S, S24C and S205C mutations of Bcl-
2Δ21 respectively were designed and ordered from Integrated DNA Technologies, 
Inc., Coralville, IA. Plasmid DNA was isolated from E. coli host strain containing the 
pGEX3T vector of GST-Bcl-2Δ21 fusion protein. The mutagenesis reactions were 
performed using the Quick-change Multi Site-Directed Mutagenesis Kit (catalog 
no.200514, Stratagene, La Jolla, CA) according to the protocol provided with the kit. 
The Polymerase Chain Reaction (PCR) is used to synthesize mutant DNA strands 
starting with purified plasmid DNA and synthetic oligonucleotide primers. The PCR 
process was completed using a thermal cycler (Mastercycler personal, Eppendorf 
Scientific, Inc., New York, U.S.A.). After the transformation process, mutant plasmid 
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DNA was isolated from several clones and the DNA samples were submitted to 
Northwoods DNA, Inc. Solway, MN for DNA sequencing. 
 
3.2.2: Protein expression and purification. 
 The successful clones containing G145E, S24C/C158S and S205C/C158S 
mutations were selected for protein expression and purification. The protein 
expression and purification procedure is described in Chapter 2 under Section 2.2.1 
and this procedure yielded ca. 150 µg of G145E mutant and 25 µg  each of  
S24C/C158S and  S205C/C158S mutants per liter of LB medium as measured by a 
Coomassie Plus protein assay (Pierce, Rockford, IL). Purified proteins were subjected 
to SDS-PAGE, analyzed by western blotting (WB) with Bcl-2 antibody, and also 
using mass spectrometry after in-gel tryptic digestion. 
 
 
3.2.3: Ca2+-ATPase activity assay in the presence of Bcl-2Δ21 mutants.   
Prior to the measurement of the activity of SERCA, the SR samples were 
incubated with WT and the mutants of Bcl-2Δ21 as follows. Three SR samples were 
prepared by diluting the concentrated SR vesicle suspension (ca. 20 mg of SR 
protein/mL)  in STE buffer (7.5 mM Tris (pH 8.0), 150 mM NaCl, and 3 mM EDTA), 
the  buffer used for purification and storage of Bcl-2Δ21, so that the contribution 
from the SR storage buffer to the final reaction mixture is <5%. The final 
concentration of SR proteins in these samples was 1 mg/mL.  WT and the G145E 
mutant of purified Bcl-2Δ21 were added separately into two of these diluted SR 
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samples. The concentration of Bcl-2Δ21 (WT or G145E) in these two samples was 
0.5 mg/mL. The third sample was the control reaction without Bcl-2Δ21. All three 
samples were incubated in 1.5 mL Eppendorf tubes at 37oC using a dry thermostat 
without agitation. Aliquots of each sample were used to measure the activity as 
explained in the next paragraph.  Protease inhibitor PMSF (1 mM) was used in each 
sample to prevent proteolytic degradation. Two similar experiments were performed 
using S24C/C158S or S205C/C158S in place of the G145E mutant. The final 
concentrations of Bcl-2Δ21 (WT or Cys-mutants) and SR proteins in these 
experiments were 0.4 mg/mL and 0.8 mg/mL, respectively.  
 The Ca2+ dependent ATPase activity assay was performed according to the 
procedure previously reported (9). Briefly, total and basal ATPase activities of the 
above mentioned SR samples were measured at 25°C over time using the colorimetric 
assay for inorganic phosphate (Pi). The Ca2+ dependent ATPase activity of the 
samples was calculated by subtracting the basal activity, measured in the presence of 
EGTA, from the total activity, measured in the presence of CaCl2. Measured activity 
using this method is the Ca2+ dependent ATPase activity of SERCA since it has been 
shown previously that this activity can be completely inhibited by the addition of 
thapsigargin, a well known inhibitor of SERCA (9).   
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3.2.4: Sucrose Density Gradient (SDG) fractionation of SR in the presence of Bcl-
2Δ21 mutants. 
Prior to the SDG fractionation, the SR samples were incubated with WT and 
the three mutants of Bcl-2Δ21 as follows: Four 20 µg samples of concentrated SR 
vesicle suspension (ca. 20 mg of SR protein/mL) were diluted in STE buffer so that 
the contribution from the SR storage buffer to the final medium is <5%.  The final 
concentration of SR proteins in these samples was 0.3 mg/mL.  Purified WT and Cys-
mutants (S24C/C158S and S205C/C158S) of Bcl-2Δ21 (10 µg each) were added 
separately into three of these diluted SR samples. The fourth sample was the control 
reaction without Bcl-2Δ21. All four samples were incubated in 1.5 mL Eppendorf 
tubes at 37°C for two hours using a dry thermostat without agitation. Protease 
inhibitor PMSF (1 mM) was used in each sample to prevent proteolytic degradation. 
In another similar experiment, G145E mutant was used in place of the Cys-mutants.  
After incubation, samples were subjected to SDG fractionation using the 
reported procedure (6). After the fractionation, the first 2 mL fraction from the top of 
the gradient of each sample was discarded. In the experiment with Cys-mutants, four 
fractions (two 1 mL fractions and two 3.5 mL fractions) and, in the experiment with 
the G145E mutant, eight fractions (six 1 mL fractions and two 1.5 mL fractions)   
were collected from the top to the bottom of the gradient. The fractions of each 
sample were analyzed by western blotting with SERCA antibody after SDS-PAGE. 
For the western blot analysis, 12.5 µL, 18.7 µL and 43.7 µL were used from 1mL, 1.5 
mL and 3.5 mL fractions, respectively. 
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3.2.5: Immunoprecipitation and GST- Bcl-2Δ21 binding assay. 
For the GST-Bcl-2Δ21 binding assay, 100 µg of SR were solubilized in 150 
µL of lysis buffer (10 mM Tris (pH 7.4), 10 mM EDTA, 1% Nonidet P40, 1 mM 
PMSF and protease inhibitors (Roche Diagnostics)). This was incubated with 10 µg 
of GST-Bcl-2Δ21 (WT or mutants) for 2 h at 4°C. As a control, another 100 µg of SR 
were solubilized in 150 µL of lysis buffer and incubated without GST-Bcl-2Δ21. The 
samples were incubated with 30 µL (packed volume) of pre-washed glutathione-
agarose beads for another 2 h at 4°C. The beads were spun down at 10000g and 
washed three times with lysis buffer and another three times with STE. STE (30 µL) 
was added and boiled for 5 min with sample buffer (2% SDS, 10% glycerol, 125 mM 
Tris pH 6.8) followed by western blot analysis after SDS-PAGE. 
For immunoprecipitation, 50 µg of SR were solubilized in 150 µL of lysis 
buffer and precleared  with 30 µL of pre-washed Protein A-agarose beads (Sigma, St. 
Louis, MO) for 15 min at 4oC. After removing the beads by centrifugation, the 
supernatant was incubated, first with 8µg of Bcl-2Δ21 (WT or mutants) for 1 h at 4oC 
and second, with 5 µL of Bcl-2 antibody for another 1 h at 4oC. Then 30 µL of pre-
washed Protein A-agarose beads were added to each sample. After 2 h of incubation 
at 4oC, the Protein A-agarose beads with bound immunocomplex were spun down, 
washed three times with lysis buffer and three times with STE and re-suspended in 30 
µL of STE buffer. Finally the samples were boiled with sample buffer and analyzed 
by western blotting after SDS-PAGE. 
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3.2.6: Comparison of WT and Cys-mutants of Bcl-2Δ21 in cysteine derivatization: 
The wild type (with or without 0.2% SDS) and the two Cys-mutants of Bcl-
2Δ2 with final concentrations of 1 μM each were incubated with 20 μM ThioGlo1 for 
1 h at 37°C in 200 mM phosphate buffer (pH 7.4). 1 ml of each of these samples was 
used to measure the fluorescence of ThioGlo1-cysteine adducts, at excitation and 
emission wavelengths of 379 nm and 513 nm, respectively. A Shimadzu RF5000U 
fluorescence spectrophotometer was used for measurements.  
 
3.2.7: Photo cross-linking of Bcl-2Δ21 mutants with SERCA using BPM.   
 BPM labeling of Bcl-2Δ21 and the photo cross-linking reactions were 
performed as described in Chapter 2 under Sections 2.2.4 and 2.2.7. Both wild type 
and the three mutants of Bcl-2Δ21 were used in the experiment. 
 
3.2.8: Details of SDS-PAGE and Western Blotting.  
Samples boiled with the sample buffer were separated on precast 4-20% 
gradient gels from Bio-Rad Laboratories (Hercules, CA) or Invitrogen (Carlsbad, CA) 
using tris-glycine running buffer. For MS analysis, the gels were stained with 
Coomassie Blue protein staining reagent. For WB analysis, the gels were 
electroblotted onto 0.45 µm polyvinylidinedifluoride (PVDF) membrane (Millipore, 
Bedford, MA) and an ECL detection kit (GE Healthcare, UK) was used to visualize 
the spots according to the manufacturer’s procedure. 
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3.3: Results and Discussion. 
3.3.1: Mutants of Bcl-2Δ21.  
 
As mentioned previously, due to the difficulty in BPM labeling of Cys158, 
which is located in a hydrophobic groove of Bcl-2Δ21, the Cys-mutants were 
generated by converting well exposed Ser residues into Cys. The rather buried 
Cys158, the only Cys residue of Bcl-2Δ21, was converted to Ser. Even though 
attempts were made to mutate several Ser residues the first mutagenesis trial resulted 
in only two successful S→C/C→S substitutions, S24C/C158S and S205C/C158S. 
The DNA sequencing data clearly show the presence of the two Cys-mutant clones 
(S24C/C158S, S205C/C158S) and also the third mutant G145E, among the DNA 
samples analyzed. These clones were used for protein expression and purification. In 
addition to the DNA sequencing data, the S205→C and G145E mutations could also 
be verified using ESI-Ion trap-MS. Scheme 3.1 shows the amino acid sequence of the 
wild type Bcl-2Δ21 indicating the mutation sites of the mutants. 
 
 
SCHEME 3.1: Amino acid sequence of wild type Bcl-2Δ21: the mutation sites are 
indicated in red.  
MAHAGRTGYD NREIVMKYIH YKLSQRGYEW DAGDVGAAPP
GAAPAPGIFS SQPGHTPHPA ASRDPVARTS PLQTPAAPGA 
AAGPALSPVP PVVHLTLRQA GDDFSRRYRR DFAEMSSQLH 
LTPFTARGRF ATVVEELFRD GVNWGRIVAF FEFGGVMCVE 
SVNREMSPLV DNIALWMTEY LNRHLHTWIQ DNGGWDAFVE 
LYGPSMRPLF DFSWLSLK 
10 20 30 40 1 
81 
121 
41 
161 
201 
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FIGURE 3.1: Mutants of Bcl-2Δ21: (a) Schematic showing different regions of the 
Bcl-2 molecule; the mutation sites are labeled in red; nine alpha helices (α1-α9), the 
flexible loop domain (FLD), four Bcl-2 homology domains (BH1-BH4) and trans 
membrane domain (TM) are indicated along with the starting and ending residue 
numbers of each domain (14). (b) 3-D structure of Bcl-2 indicating the location of the 
mutation sites (Picture was generated using PDB file 1G5M with Molecular 
Visualization Resources of Molviz.org) 
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The Figure 3.1 shows the mutation sites in a schematic diagram and also with 
respect to the 3-D structure of Bcl-2. In S24C/C158S, the S→C substitution site, 
Ser24, is located in α1 of the BH4 domain. Even though this N terminal region has 
been identified as an essential region for apoptosis inhibition by Bcl-2, the S24 in 
particular is not an essential residue as revealed by studies based on S24→G 
conversion (15). Therefore the S24→C mutation should not have any effect on the 
activity of Bcl-2Δ21. On the other hand the S205→C mutation in the S205C/C158S 
mutant is located right next to C terminal end of the BH2 domain. The conversion of 
S205→C also should not have any effect on the activity of Bcl-2Δ21 since the 
truncated form, Bcl-2(1-203) is still active in cell protection (16). Since the oxidation of 
C158 has been reported to have no effect on the action of Bcl-2Δ21 on SERCA 
inactivation (9), the C158→S substitution is also expected to have no effect on the 
activity of Bcl-2Δ21. The fourth mutation site, G145 on the other hand, is a highly 
conserved residue in the Bcl-2 family and also it has been identified as a critical 
residue in anti-apoptotic action of Bcl-2. The G145E mutant has been reported to 
completely diminish anti-apoptotic activity of human Bcl-2 (2, 3). Therefore the 
G145E mutant is expected to show no/less effect on SERCA inactivation. 
After the purification of the three mutant proteins of Bcl-2Δ21 (G145E, 
S24C/C158S and S205C/C158S), the concentrations were determined by Coomassie 
Plus protein concentration assay. As revealed by the assay, the amount of G145E 
mutant produced is about two times that of the WT whereas that of the two Cys-
mutants is about 1/3 of the WT level. These differences are probably due to some 
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alterations in hydrophobicity of the molecule caused by the mutations. The 
hydrophobicity should be lower in G145E while it should be higher in the two Cys-
mutants with respect to the WT molecule. As seen in the western blot (Figure 3.2) all 
three mutants and the WT protein have the same affinity for the anti Bcl-2 antibody. 
The less intense band below the 25 kDa mark can be assumed to be a hydrolytic 
and/or proteolytic product of Bcl-2Δ21. 
 
 
FIGURE 3.2: Wild type and mutants of Bcl-2Δ21 analyzed by western blotting 
with Bcl-2 antibody: 1-wild type, 2- S24C/C158S, 3-S205C/C158S, and 4-G145E of 
Bcl-2Δ21. 
 
 
3.3.2: Effect of mutants of Bcl-2Δ21 on Ca2+-ATPase activity of SERCA. 
Even though the two Cys-mutants were generated primarily targeting the 
cross-linking experiments, they were used in the activity assay experiments along 
with G145E mutant, to study their effect on SERCA inactivation. Samples of SR 
were co-incubated with the WT or mutants of Bcl-2Δ21 prior to the activity 
measurements. A molar ratio of 2:1 (Bcl-2Δ21: SERCA) was used since complete 
inactivation of SERCA was reported after 2 hours of co-incubation at this ratio (6,9). 
Also some important control experiments have been reported previously, confirming 
that this SERCA inactivation is specifically caused by Bcl-2Δ21(9). Figures 3.3 and 
25kDa 
1 2 3 4 
Bcl-2Δ21  
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3.4 show the variation of Ca2+-ATPase activity of SERCA over time, indicating how 
the three mutants affect SERCA activity.  
Since G145E is a loss-of-function mutant of human Bcl-2 as reported in a 
study using mammalian cell lines (3), one could expect to see no/smaller effect on 
SERCA inactivation from  this mutant compared to WT Bcl-2Δ21. As expected, 
G145E mutant did not change the activity of SERCA significantly even after 4 hours 
of incubation (Figure 3.3). This clearly demonstrates that the G145 of Bcl-2Δ21 is a 
critical hot spot for the inactivation of SERCA. 
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FIGURE 3.3: Effect of the G145E mutant of Bcl-2Δ21 on the activity of SERCA: 
The graph shows the Ca2+-ATPase activity (ratio to control) over time, without Bcl-
2Δ21(blue line), in the presence of WT (purple line) and the G145E mutant (red line) 
of Bcl-2Δ21.  
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The two Cys-mutants were expected to show a similar effect as the WT Bcl-
2Δ21 on the inactivation of SERCA. Interestingly and surprisingly the two Cys-
mutants acted as gain-of-function mutants and SERCA was inactivated to a higher 
extent than with WT Bcl-2Δ21 (Figure 3.4). Complete inactivation of SERCA is 
observed even after 1 ½ hours of co-incubation with the Cys-mutants.  
Considering all three mutants together, the more hydrophobic Cys-mutants are 
more efficient while the less hydrophobic G145E mutant shows less SERCA 
inactivation, suggesting that hydrophobicity of the Bcl-2Δ21 molecule is important 
for SERCA/Bcl-2Δ21 interactions. Hydrophobicity of Bcl-2Δ21 might facilitate 
association with SERCA and/or incorporation of Bcl-2Δ21 into the SR membrane 
thus inactivating SERCA faster. 
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FIGURE 3.4: Effect of the Cys-mutants of Bcl-2Δ21 on the activity of SERCA: (a) 
Effect of S24C/C158S; (b) Effect of S205C/C158S; The graphs show the Ca2+-
ATPase activity (ratio to control) over time, without Bcl-2Δ21(blue lines), in the 
presence of WT (purple lines) and  the Cys-mutants (red lines) of Bcl-2Δ21.  
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3.3.3: Effect of mutants of Bcl-2Δ21 on Sucrose Density Gradient (SDG) 
fractionation of SR. 
Using SDG fractionation, it was shown previously by Dremina et al that 
SERCA is localized in Caveolae-Related Domains (CRD) of the SR membrane (6). 
The location of this CRD fraction is indicated in the simulated sucrose gradient in 
Figure 3.5. 
 
FIGURE 3.5: Simulated sucrose gradient after fractionation of SR: CRD fraction 
(number 2) is localized between 5% and 38% sucrose. 
 
After the co-incubation with SR, Bcl-2Δ21 is incorporated into CRD, 
colocalized with SERCA and also induces translocation of SERCA from CRD. Partial 
unfolding of SERCA was also seen along with the inactivation and translocation (6, 
9). Figure 3.6 is a schematic showing the location of SERCA in the SR/ER membrane 
before and after the incubation with Bcl-2Δ21. 
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FIGURE 3.6: Location of SERCA in SR/ER membrane: before and after the 
incubation with Bcl-2Δ21. 
 
The three mutants of Bcl-2Δ21 were compared with WT for their ability to 
induce translocation of SERCA from the CRD of the ER/SR membrane.  The SR 
samples were incubated with Bcl-2Δ21 (WT or the three mutants) before the SDG 
fractionation. The location of SERCA within the gradient after SDG fractionation was 
determined using western blotting with a SERCA antibody. These western blots are 
shown in Figure 3.7. The results with the two Cys-mutants are shown in the Figure 
3.7-a while Figure 3.7-b shows the results for the G145E mutant. Lane 2 of each 
sample represents the CRD fraction. The SR samples without Bcl-2Δ21 show almost 
all SERCA in the low density CRD fraction (Lane 2 of Figure 3.7-a(i) and b(i)) 
whereas the SR samples with WT Bcl-2Δ21 show SERCA even in the high density 
bottom fraction (Lane 4 of Figure 3.7-a(ii) and Lane 8 of b(ii)). This observation is 
consistent with previously published data, i.e. when SERCA is inactivated by Bcl-
2Δ21, it is translocated from CRD to a different membrane environment and therefore 
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SERCA can be seen even in the high density bottom fraction of the sucrose gradient 
(6). 
 
 
FIGURE 3.7: Effect of mutants of Bcl-2Δ21 on Sucrose Density Gradient (SDG) 
fractionation of SR: SDG fractions probed with SERCA antibody; (a) Experiment 
with the Cys-mutants; (i) SR alone, (ii)SR incubated with WT, (iii) SR incubated with 
S24C/C158S and (iv) SR incubated with S205C/C158S. (b) Experiment with G145E 
mutant; (i) SR alone, (ii) SR incubated with WT, (iii) SR incubated with G145E. 
 
 
Since the two Cys-mutants showed higher SERCA inactivation, one could 
expect to see translocation of more SERCA from the CRD of the SR membrane. If 
this is true the samples incubated with the Cys-mutants should show less SERCA in 
the low density CRD fraction and more SERCA in the high density bottom fraction, 
compared to the sample incubated with the wild type Bcl-2Δ21. As expected, bottom 
SR incubated 
with Bcl-2Δ21 
(S24C/C158S)  
Top Bottom 
SR alone 
SERCA 
1 2 3 4 
SR incubated with 
Bcl-2Δ21  (WT)  
SR incubated 
with Bcl-2Δ21 
(S205C/C158S) 
(i) 
(ii) 
(iii) 
(iv) 
SR incubated 
with Bcl-2Δ21    
(G145E) 
SR incubated 
with Bcl-2Δ21 
(WT) 
SR alone 
1 2 3 4 8 7  6 5 
(b) 
(i)
(ii)
(iii)
Bottom Top 
Fraction number
SERCA 
(a) 
 116
fractions of the SR samples incubated with Cys-mutants (Lane 4 of Figure 3.7-a (iii) 
and (iv)) show more SERCA. The G145E mutant, on the other hand, showed less 
SERCA inactivation and hence no/less translocation of SERCA with the G145E 
mutant can be expected and, if this is true, the sample incubated with the G145E 
mutant should indicate more SERCA in the low density CRD fraction and less 
SERCA in the high density bottom fraction, compared to the sample incubated with 
the wild type Bcl-2Δ21. As seen in the Figure 3.7-b, the SR sample incubated with 
G145E mutant shows more SERCA in the CRD fraction and no/less SERCA in the 
bottom fraction (compare Lanes 2 and 8 of Figure 3.7-b (iii)). These results further 
confirm the correlation between SERCA inactivation and translocation, the more 
inactivation the more translocation. 
 
3.3.4: Association of SERCA with mutants of Bcl-2Δ21; Using GST-Bcl-2Δ21 
binding assay and immunoprecipitation.  
To compare the ability of Bcl-2Δ21 mutants to associate with SERCA, a GST-
Bcl-2Δ21 binding assay and immunoprecipitation (IP) was employed. Figure 3.8-a 
shows the binding assay samples probed with Bcl-2 antibody.  In addition to the 
50kDa GST-Bcl-2Δ21 band, a degradation product of the fusion protein is seen. 
Further the WB shows less fusion protein of S24C/C158S mutant (Lane 2 in a) 
suggesting relatively lower stability of this mutant and this affects the comparison of 
this Cys-mutant with the others for their binding ability with SERCA. However, WT, 
S205C/C158S and G145E samples show almost the same amount of fusion protein 
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(Lanes 1, 3 and 4 in Figure 3.8-a) and therefore those three can be compared with 
each other for their binding ability with SERCA.  
The SERCA antibody WB of the binding assay samples is shown in Figure 
3.8-b. Since all three mutant samples show the SERCA band (Lanes 5, 6, 7 in Figure 
3.8-b), fusion proteins of the three mutants of Bcl-2Δ21 can directly bind with 
SERCA. However, the S205C/C158S sample shows less SERCA (Lane 6 in b) while 
the G145E sample shows more SERCA (Lane 7 in b) compared to the WT sample 
(Lane 4 in b). Since, irreversible inactivation of SERCA is faster with the 
S205C/C158S mutant, availability of  less native SERCA for association with Bcl-
2Δ21 can be suggested. Also the opposite argument explains the more intense 
SERCA band seen with the G145E mutant. The control sample, without GST-Bcl-
2Δ21 shows no SERCA (Lane 3 in b) confirming there is no affinity of SERCA for 
glutathione-agarose beads. Further, it has been reported previously that GST itself has 
no affinity for SERCA (9). Therefore SERCA seen in the binding assay samples is 
due to the association with Bcl-2Δ21. However, there might be some other 
unidentified protein/proteins in the SR helping this SERCA/ Bcl-2Δ21 association. 
 
 118
 
 
FIGURE 3.8: Association of SERCA with mutants of Bcl-2Δ21; Using GST-Bcl-
2Δ21 binding assay: (a) western blot with Bcl-2 antibody; 1-with WT, 2-with 
S24C/C158S, 3-with S205C/C158S and 4-with G145E of GST-Bcl-2Δ21. 5-control 
sample without GST-Bcl-2Δ21. (b) western blot with SERCA antibody; 1-molecular 
weight marker, 2-fraction of purified SR vesicles, 3-control sample without GST-Bcl-
2Δ21, 4-with WT, 5-with S24C/C158S, 6-with S205C/C158S and 7-with G145E of 
GST- Bcl-2Δ21.  
 
 
Immunoprecipitation using Bcl-2 antibody was also employed to further 
confirm the ability of Bcl-2Δ21   mutants to directly associate with SERCA. Figure 
3.9-a shows IP samples in the WB with Bcl-2 antibody. As seen with the GST-Bcl-
2Δ21 binding assay, the IP sample of S24C/C158S shows less Bcl-2Δ21 (Lane 3 in 
Figure 3.9-a) further confirming that this mutant is relatively more susceptible to 
degradation during the hours of incubation. WT and the other two mutants, 
S205C/C158S and G145E, are almost the same in stability and show similar amounts 
of Bcl-2Δ21 in the samples (Lanes 2, 4 and 5 in Figure 3.9-a).  
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FIGURE 3.9: Association of SERCA with mutants of Bcl-2Δ21; Using 
immunoprecipitation: (a) western blot with Bcl-2 antibody; 2-with WT, 3-with 
S24C/C158S, 4-with S205C/C158S and 5-with G145E of Bcl-2Δ21. (b) western blot 
with SERCA antibody; 2-fraction of purified SR vesicles, 3-with WT, 4-with 
S24C/C158S, 5-with S205C/C158S and 6-with G145E of Bcl-2Δ21.  
 
The WB with SERCA antibody (Figure 3.9-b) shows SERCA with all four 
samples further confirming that, not only the WT but also the three mutants are 
capable of directly binding to SERCA. However, the intensities of the SERCA bands 
with both WT and the mutants are the same and do not show a pattern identical to the 
GST-Bcl-2Δ21 binding assay samples (Lanes 3, 4, 5, 6 of Figure 3.9-b). During IP, 
both Bcl-2Δ21 antibody and SERCA are competing with each other for association 
with Bcl-2Δ21. Furthermore, the irreversible inactivation of SERCA caused by 
interaction with Bcl-2Δ21 could lower the amount of native SERCA available for IP. 
For these reasons, the amount of SERCA immunoprecipitated does not accurately 
reflect the relative affinity of the three Bcl-2Δ21 mutants for the association with 
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SERCA. The band at 50kDa in the western blots of immunoprecipitates is probably 
due to non-specific binding of Bcl-2 antibody and SERCA antibody with the light 
chain of the Bcl-2 antibody used for IP. 
 
3.3.5: Comparison of WT and Cys-mutants of Bcl-2Δ21 in cysteine derivatization: 
As mentioned earlier, the two Cys-mutants, S24C/C158S and S205C/C158S, 
were generated primarily for photo cross-linking experiments. Since S24 and S205 
are well exposed residues, higher efficiency in cysteine derivatization is expected 
with the C24 and C205 of the two Cys-mutants. As expected the two Cys-mutants are 
more susceptible efficient than wild type to cysteine derivatization as revealed by 
ThioGlo1-Cysteine adduct formation (Figure 3.10).  However, compared to the wild 
type Bcl-2Δ21 with added SDS, the mutants show only about a 10% increase in 
labeling efficiency (Figure 3.11). Therefore BPM derivatization of the Cys-mutants, 
for photo cross-linking experiments, was also achieved in the presence of 0.05% SDS 
in order to have more BPM labeled molecules. After the BPM labeling reaction, the 
added SDS was removed from the reaction mixture by dialysis before cross-linking 
with SERCA. 
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FIGURE 3.10: Comparison of the Cys-mutants with wild type Bcl-2Δ21 (without 
SDS) for cysteine derivatization, as determined by ThioGlo1-Cystein adduct 
formation: (1)-Wild type, (2)-S24C/C158S and (3)-S205C/C158S of Bcl-2Δ21.  
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FIGURE 3.11: Comparison of the Cys-mutants with wild type Bcl-2Δ21 (with 
SDS) for cysteine derivatization, as determined by ThioGlo1-Cystein adduct 
formation: (1)-Wild type (without SDS), (2)-S24C/C158S and (3)-S205C/C158S and 
(4)Wild type (with SDS).  
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3.3.6: Mutants of Bcl-2Δ21 in photo cross-linking with SERCA. 
Figures 3.12 and 3.13 are the western blots with Bcl-2 and SERCA antibodies, 
respectively, of the photo cross-linked samples.  In the WB of the Bcl-2 antibody 
(Figure 3.12), the wild type Bcl-2Δ21 clearly shows (Lanes 2 and 3 of Figure 3.12)  
two bands at 135kDa and 160kDa corresponding to the two cross-linked products of 
1:1 and 2:1 molar ratio of Bcl-2Δ21: SERCA, respectively. The photo cross-linking 
of wild type Bcl-2Δ21 with SERCA is discussed in Chapter 2 under Section 2.3.4. 
Since the Cys158 of the BH1 domain is the site of cross-linking reagent in the wild 
type Bcl-2Δ21, it was concluded that the BH1 domain of the hydrophobic groove of 
Bcl-2Δ21 is in direct contact with SERCA. 
When Bcl-2Δ21 mutants are considered, even though the G145E mutant 
shows loss-of-function on SERCA inactivation, it shows clear cross-linked products 
and also homodimers   with intensities comparable to the WT (compare Lane 9 with 
Lane 3 of Figure 3.12). As with WT Bcl-2Δ21, the site of cross-linking in the G145E 
mutant is also Cys158.  Therefore the cross-linking results with the G145E mutant 
further support the suggestion that the SERCA interaction surface of Bcl-2Δ21 
involves the BH1 domain. As mentioned before, Bcl-2Δ21 homodimerization 
involves two binding surfaces, the acceptor and the donor surfaces. It is known that 
G145 is located in the middle of the acceptor surface of Bcl-2Δ21 homodimers (17). 
The lower intensity of the dimer (50 kDa band) of the G145E mutant compared to the 
WT (compare Lane 8 with Lane 2 of Figure 3.12) indicates some negative effect on 
homodimerization by the G145E mutant. However it is interesting to notice 
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comparable levels of homodimers of both the WT and G145E mutant in the presence 
of the SR. Even though the G145E mutant lowers homodimerization ability, the 
availability of SR vesicle membrane compensates for it.  The SR/BPM control sample 
shows no bands in the WB (Lane 10 of Figure 3.12) confirming the absence of any 
non-specific binding of Bcl-2 antibody with SR proteins.    
 
FIGURE 3.12: Bcl-2 antibody western blot of photo cross-linked samples: Lanes 3, 
5, 7 and 9 are samples of Bcl-2Δ21/BPM/SR of WT, S24C/C158S, S205C/C158S 
and G145E of Bcl-2Δ21, respectively. Lanes 2, 4, 6 and 8 are the corresponding 
control samples of Bcl-2Δ21/BPM. Lane 10 is the SR/BPM control sample. Lane 1 is 
the molecular weight marker.  
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The fast inactivation of SERCA by the two Cys-mutants would affect the 
cross-linking with SERCA and therefore the cross-linking results would not be 
comparable with that of the wild type results. As revealed by the binding assay and IP 
experiments the S24C/C158S mutant is less stable and degrades faster. Consistent 
with this observation, the photo cross-linking sample of the S24C/C158S mutant 
shows less monomer compared to the other samples (Figure 3.12; compare the band 
at 25 kDa of Lanes 4 and 5 with others). However, the S24C/C158S mutant samples 
clearly show the absence of the cross-linked products and homodimers. The absence 
of cross-linked bands would indicate that the site of cross-linking reagent in this 
mutant, Cys24, and hence the BH4 domain, is not sufficiently close to the SERCA 
interaction surface. On the other hand, since the inactivation and translocation of 
SERCA by this mutant is much faster, there might not be enough Bcl-2Δ21-
associated SERCA available for cross-linking during UV irradiation. Even though 
BH4 is a part of the Bcl-2 donor surface for homodimerization (17), Cys24 in 
particular might not be sufficiently close to covalently link with the other 
S24C/C158S molecule of the homodimer.   
The S205C/C158S mutant, on the other hand, shows both cross-linked 
products and homodimers (Figure 3.12; Lanes 6 and 7). However the intensities of 
these bands are lower, relative to the WT bands. The cross-linking site, Cys205 in the 
S205C/C158S mutant is located closer to the BH2 domain, which is a part of the 
hydrophobic surface groove of Bcl-2Δ21. Therefore not only the BH1 domain (as 
seen with the WT and the G145E mutant) but also the BH2 domain of Bcl-2Δ21 
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should be interacting with SERCA. Nevertheless the BH2 domain is a part of the 
acceptor surface of Bcl-2 homodimers (17) and therefore the appearance of the 
homodimers in the cross-linked sample is acceptable. As with S24C/C158S mutant, 
the argument based on fast SERCA inactivation, can be made here too, explaining the 
lower intensity of the cross-linked bands. This argument was facilitated by the finding 
that the incubation time of the SERCA/Bcl-2Δ21 mixture prior to the UV irradiation 
is critical for observation of cross-linked products. Clear cross-linked bands were 
seen only with 15 min of incubation and longer incubation times (45 min and 2 hours) 
did not show cross-linked products with both Cys-mutants (data not shown). 
The SERCA antibody WB of the cross-linked samples is shown in Figure 
3.13. It was noticed previously (Chapter 2) that the photo cross-linked sample of Bcl-
2Δ21/BPM/SR of wild type protein and the SR/BPM control sample show identical 
results and therefore SERCA/Bcl-2Δ21 cross-linked bands could not be confirmed 
with SERCA antibody. Similar to the results with wild type Bcl-2Δ21, the results of 
the cross-linked samples of Bcl-2Δ21/BPM/SR of the three mutants (Lanes 3-6 in 
Figure 3.13) and also of the SR/BPM control sample (Lane 2 of Figure 3.13) are 
identical. Therefore the discussion about the SERCA antibody western blot of the 
photo cross-linked samples with wild type Bcl-2Δ21, is applicable here too (see 
Chapter 2, Section 2.3.4). Even though the same amount of protease inhibitor is used 
in all cross-linking samples, the two Cys-mutant samples show higher SERCA 
degradation (bands below 100 kDa in Lanes 4 and 5 in Figure 3.13). This could be 
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caused by relatively higher inactivation and translocation of SERCA by these Cys-
mutants.  
 
 
 
FIGURE 3.13: SERCA antibody western blot of photo cross-linked samples: 
Lanes 3, 4, 5 and 6 are samples of Bcl-2Δ21/BPM/SR of WT, S24C/C158S, 
S205C/C158S and G145E of Bcl-2Δ21, respectively. Lane 2 is the SR/BPM control 
sample without Bcl-2Δ2. Lane 7 is a fraction of purified SR vesicles. Lanes 1, 8 are 
the molecular weight marker.  
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3.4: Conclusions.   
In conclusion, the experiments described in this chapter further confirm that 
Bcl-2Δ21 and SERCA can interact with both 1:1 and 2:1 (Bcl-2Δ21: SERCA) molar 
ratios. All three mutants of Bcl-2Δ21 (S24C/C158S, S205C/C158S and G145E) can 
directly associate with SERCA. The G145E mutant is a loss-of-function whereas the 
two Cys-mutants, S24C/C158S and S205C/C158S, are gain-of-function on SERCA 
inactivation and translocation. The conserved residue, G145, is a critical hot spot for 
Bcl-2Δ21-mediated inactivation and translocation of SERCA. Fulfilling the second 
objective of the work reported in this dissertation, the BH1and BH2 domains of Bcl-
2Δ21 are identified as directly involved in the interactions with SERCA. The trans 
membrane domain of Bcl-2 is not required for this interaction. 
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Chapter 4:  
Overall discussion, conclusions and future experiments.  
 
4.1: Overall discussion and conclusions. 
Bcl-2 regulated changes in the Sarco/Endoplasmic Reticulum (SR/ER) Ca2+ 
level have been subjected to investigation by various groups (1-5). Interaction of Bcl-
2 with different ER proteins such as Inositol tris phosphate receptor (IP3R) (6), and 
SERCA (7-9) was reported recently, attempting to answer the question “How does 
Bcl-2 regulate the SR/ER Ca2+ level?” It has been reported that both full length Bcl-2 
and the truncated form, Bcl-2Δ21, can directly associate with and inactivate SERCA. 
Under normal conditions SERCA is mainly localized in low density Caveolae-
Related Domains (CRD) of the SR/ER membrane. After association with Bcl-2, 
SERCA is translocated to a different high density region of the SR/ER membrane (8, 
9). In the present study important characteristics of the SERCA/Bcl-2 interactions 
were unraveled including the identification of the critical residues/domains of the 
interface of the two proteins.  
The wild type and also the three mutants, S24C/C158S, S205C/C158S and 
G145E of the truncated form of Bcl-2, Bcl-2Δ21 were used in the experiments. All 
anti-apoptotic proteins including Bcl-2 have nine alpha helices and four BH domains 
(BH1-4). They have a common hydrophobic surface groove formed by the BH1-3 
domains which are important in heterodimerization with pro-apoptotic members (10, 
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11).  The truncated form, Bcl-2Δ21, contains only eight alpha helices since it lacks 
the α9/TM domain.  
Cross-linking was utilized to identify the sites/domains of SERCA/Bcl-2Δ21 
interaction surface. This method has been used for decades in protein interaction 
studies. When the interface of interacting proteins are identified through cross-
linking, the site of cross-linking reagent is a key factor. If it is too close to the 
interface or at a site, directly involved in the interaction, it might block the proteins 
interacting with each other. On the other hand if it is too far from the interface, even 
though the proteins are interacting, the reagent is not sufficiently close to crosslink 
the interaction partners. Benzophenone-4-maleimide (BPM), photo activatable cross-
linking reagent used in this study is attached to Cys158 in the case of WT and also of 
the G145E mutant of Bcl-2Δ21. As previously reported the redox status of Cys158 
does not affect the Bcl-2Δ21-mediated inactivation of SERCA (8). Therefore BPM 
attachment to Cys158 of Bcl-2Δ21 can be expected not to affect the SERCA/Bcl-
2Δ21 association. In fact BPM treated Bcl-2Δ21 can effectively inactivate SERCA as 
revealed by a Ca2+-ATPase activity assay. After photo cross-linking both WT and the 
G145E mutant show cross-linked products confirming that Cys158 is located closer 
to the SERCA/Bcl-2Δ21 interface. The Cys158 is located in the BH1 domain, one of 
the three domains of the hydrophobic surface groove of Bcl-2. Therefore the BH1 
domain and hence the hydrophobic surface groove of Bcl-2 must be directly 
interacting with SERCA. 
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In the Cys-mutants, S24C/C158S and S205C/C158S, the site of BPM 
activation is Cys24 and Cys 205, respectively. Cys24 is located in BH4 domain while 
Cys205 is right next to the C-terminal end of the BH2 domain of Bcl-2Δ21. Based on 
the cross-linking results with the S24C/C158S mutant, the BH4 domain is not a 
partner of the SERCA/Bcl-2Δ21 interface whereas the cross-linking results of the 
S205C/C158S mutant suggest that the BH2 domain is a part of the SERCA/Bcl-2Δ21 
interface.  
Importantly, as evident from cross-linking results, both one or two molecules 
of Bcl-2Δ21 can interact with SERCA. In the SERCA-2Bcl-2Δ21 trimer, two 
molecules of Bcl-2Δ21 could react at two separate sites on SERCA or a homodimer 
of Bcl-2Δ21 could react as a single unit, with one site of SERCA. A very small 
fraction of cross-linked products is seen in agreement with a previously suggested 
transient interaction/weak binding constant of Bcl-2Δ21 with SERCA (8,9). Only a 
small fraction of associated SERCA/Bcl-2Δ21, preventing cell death, is reasonable in 
vivo, since inactivation of all or a larger fraction of SERCA by Bcl-2Δ21 could be 
death inducible rather than protecting.  
G145 is a conserved residue in α5 of BH1, located at the bottom of the 
hydrophobic surface groove of Bcl-2 (10-12). This highly conserved G residue plays 
a crucial role in anti apoptotic activity of Bcl-2 as demonstrated by several mutations 
involving this residue. Decreased death repressor activity and the absence of 
heterodimerization with pro-apoptotic member Bax, was reported with 144WGR146 
into 144AAA146(where W-Tryptophan, G-Glycine, R-Arginine and A-Alanine), 
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G145A and G145E mutations in Bcl-2, and also with the equivalent mutation, G138A 
in Bcl-xL, a structural homolog of Bcl-2 (12). The G145E mutations in the Bcl-2 
homolog of C.elegans, CED-9, is reported as a gain-of-function mutation 
emphasizing the importance of the G145 of BH1 domain in apoptosis control (13). 
It is reported here that this conserved G residue, G145 in the α5/BH1 domain 
of the hydrophobic surface groove of Bcl-2Δ21 is important in inactivation and 
translocation of SERCA.  The G145E mutation of Bcl-2Δ21 diminished the 
inactivation and translocation of SERCA. Since this single site mutation cannot be 
tolerated, G145 of Bcl-2Δ21 must be a critical site for inactivation and translocation 
of SERCA. However, the mutant is still able to cross-link with SERCA through the 
cross-linking reagent at Cys158. This reveals that the surface of Bcl-2Δ21 of 
SERCA/Bcl-2Δ21 interface should contain several interaction sites and is not limited 
to G145.  
Glycine has the smallest side chain, a hydrogen atom, with the smallest cross 
sectional area and it facilitates proper protein folding. As a highly conserved residue, 
G145 should be critical for proper topology of the hydrophobic surface groove of 
Bcl-2Δ21 and therefore it facilitates Bcl-2Δ21 controlled SERCA inactivation and 
translocation. The G→E mutation introduces a negatively charged, larger side chain 
into the hydrophobic groove of Bcl-2Δ21, changing the characteristics of the groove. 
Probably this G→E conversion might reduce the hydrophobicity of the molecule thus 
changing electrostatic and hydrophobic interactions between the side chains of the 
SERCA/Bcl-2Δ21 interface which are important in inactivation and translocation of 
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SERCA. Also we cannot exclude that, apart from G145, there might be other residues 
in BH1, BH2 and BH3 domains of the hydrophobic surface groove of Bcl-2Δ21 
which are important in this interaction.  
The two Cys-mutants, S24C/C158S and S205C/C158S, on the other hand are 
gain-of-function on SERCA inactivation and translocation. Since C→S and S→C 
replacements in the mutants are isosteric, this gain-of-function cannot be caused by 
any alterations in steric effects. Rather these mutations might change the hydrogen 
bond network of Bcl-2Δ21, changing the overall structure of the protein. This 
structural change would facilitate the interaction of the hydrophobic surface groove of 
Bcl-2Δ21 with SERCA. Further this structural change in S24C/C158S mutant might 
affect the stability of the protein making it more susceptible to proteolytic/hydrolytic 
degradation. 
To date more than 10 different isoforms of SERCA have been identified (14). 
SERCA inserts its Ca2+ transport function through the well known E1/E2 model. The 
high Ca2+ affinity E1 conformation of SERCA changes to the low affinity E2 
conformation while actively transporting Ca2+ ions from the cytoplasm into the ER 
(15-17). SERCA is a trans-membrane protein. Its cytoplasmic head piece contains six 
subdomains. These are the N-terminal stalk domain (residues 1-40), the β-strand 
domain (residues 131-238), the phosphorylation domain (residues 328-505), the ATP 
binding domain (residues 505-680), the hinge domain (residues 681-738) and the C-
terminal region (residues 902-994). The stalk domain connects the head piece to the 
transmembrane domain. The phosphorylation domain and the ATP binding domain 
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together form the active site for ATP hydrolysis (18, 19). Inter domain interactions 
between these cytosolic domains, specifically between the ATP binding and 
phosphorylation domains are important in the Ca2+ transport mechanism of SERCA 
(20, 21).  
The SERCA peptide, 568DTPPKR573, cross-linked to the Cys158/BH1 domain 
of Bcl-2Δ21, as identified from mass spectrometry, is located at the cytoplasmic ATP 
binding domain. More importantly it is located right next to 560RCLALA565, one of 
the conserved motifs in SERCA (22). Furthermore, it has been found previously, 
using a fragment of SERCA (residues 357-600) containing the ATP binding domain, 
that Thr569 was among the residues whose backbone conformation was changed 
upon nucleotide binding, as measured using NMR spectroscopy (23). Therefore 
Thr569 and hence 568DTPPKR573 could be directly involved in ATP binding during 
the catalytic cycle of SERCA. Bcl-2Δ21 might directly but transiently interact with 
the ATP binding domain of SERCA thus blocking the cross-talk between the ATP 
binding and the phosphorylation domains, which is required for  SERCA activity. As 
reported previously, the SERCA/Bcl-2Δ21 interaction does not change the ATP 
binding affinity of the domain (9). Interaction of Bcl-2Δ21 with 568DTPPKR573 would 
not necessarily change the affinity of the domain for ATP since more than one amino 
acid residue is supporting the binding process (23-27).  Apart from this ATP binding 
domain, Bcl-2Δ21 might interact with other domains of SERCA which were not 
identified in this study. 
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 Other SR proteins which act in concert with SERCA in SR-calcium regulation 
(28) and also yet unidentified Bcl-2Δ21 and SERCA binding proteins can be involved 
in this SERCA/Bcl-2Δ21 interaction. Protective action of HSP70 (where HSP stands 
for Heat Shock Protein) on inactivation of SERCA by Bcl-2Δ21 has been reported 
(29).  As suggested by our GST-Bcl-2Δ21 binding assay, photo cross-linking and 
mass spectrometric data, Mitsugumin-29 (Mg29) could be another involved protein. 
Mg29 is a recently identified protein in the triad-junction of skeletal muscle (30). It is 
essential for proper SR membrane structure and hence for proper function of skeletal 
muscle (31). It can interact functionally with Rynodine Receptor (RyR), a calcium 
release channel in the SR membrane, leading to apoptotic cell death (32). Its 
interaction with the Store Operated Calcium channel (SOC), a channel in plasma 
membrane which mediates extracellular Ca2+ entry into the cytoplasm, has also been 
reported (33).  In addition to other possible Bcl-2Δ21 and SERCA binding proteins, 
some other factors which cannot be produced in-vitro could also be participating in 
the SERCA/Bcl-2Δ21 interactions.  
 Apart from the direct interaction, Bcl-2Δ21 might inactivate SERCA through 
some other indirect mechanisms. Truncated Bcl-2Δ21, which lacks membrane 
anchoring trans-membrane domain, is reported to have membrane insertion 
characteristics (34, 35) suggesting that Bcl-2Δ21 might inactivate SERCA indirectly 
through interactions with membrane lipids. As mentioned earlier, SERCA is mainly 
located at CRD of SR membrane and is translocated from CRD after interaction with 
Bcl-2Δ21(9). Cholesterol and Sphingolipids fall under the main lipids in CRD (36). 
 136
GM1, a glycosphingolipid highly concentrated in CRD is known to inhibit SERCA 
activity by changing the cytosolic part of SERCA into a less compact form (37) and 
this conformational change might lead to translocation of SERCA.  Bcl-2Δ21 might 
interact with GM1 in a favorable manner supporting the GM1-mediated inactivation 
and conformational change of SERCA. 
 In conclusion, the work reported in this dissertation further supports 
the previously suggested direct association of Bcl-2Δ21 with SERCA causing 
inactivation and translocation of SERCA (8, 9). Based on the cross-linking studies the 
two proteins can interact in both 1:1 and 2:1 (Bcl-2Δ21: SERCA) molar ratios. 
Fulfilling the major objectives of the project, the BH1 and BH2 domains, and hence 
the hydrophobic surface groove of Bcl-2Δ21 were identified as directly involved in 
the interactions with SERCA. The BH1 domain of Bcl-2Δ21 interacts with the 
568DTPPKR573 peptide of the ATP binding domain of SERCA. Based on the chemical 
cross-linking experiments, the distance between the interface/interfaces of Bcl-
2Δ21/SERCA complex can range from ~6-14Å.  Even though all three mutants, 
S24C/C158S, S205C/C158S and G145E of Bcl-2Δ21 studied can directly associate 
with SERCA, the G145E mutant is a loss-of-function whereas the two Cys-mutants, 
S24C/C158S and S205C/C158S, are gain-of-function on SERCA inactivation and 
translocation. Therefore the conserved residue G145 is a critical hot spot for the Bcl-
2Δ21-mediated inactivation and translocation of SERCA. Mitsugumin-29 (Mg29) 
could also be involved in Bcl-2Δ21/SERCA interactions. The association of SERCA 
with Bcl-2Δ21 is affected by aging.  
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4.2: Future Experiments. 
Some suggested experiments that would further support the studies on 
SERCA/Bcl-2 interactions are described below. Preliminary data of some initial 
experiments are also presented.  
 
4.2.1: Improvement of mass spectrometric identification of cross-linked peptides. 
 As mentioned above the SERCA peptide, 568DTPPKR573 of the ATP binding 
domain was identified cross-linked to Cys158 of wild type Bcl-2Δ21 through the 
photo cross-linking reagent, Benzophenone-4-maleimide (BPM). However, since the 
MS/MS of the cross-linked SERCA-Bcl-2Δ21 dipeptide was not found in ESI-
FTICR-MS data, the exact cross-linking site within the peptide of SERCA could not 
be confirmed. The reason for this is the lower abundance of cross-linked products in 
the sample and the problem can be overcome by using a method to enrich the sample 
with cross-linked products. Affinity purification is commonly used in this regard. 
Ni2+ affinity purified cross-linked products of His6-Bcl-2Δ17, explained in Chapter 2, 
can be analyzed by mass spectrometry after in-gel/in-solution tryptic digestion of the 
vacuum-concentrated fraction of interest. This would improve the MS data and the 
MS/MS of the cross-linked products would be seen. Alternatively a photo cross-
linking reagent with an affinity tag such as biotin can be used in cross-linking 
reactions so that the cross-linked peptides can be affinity purified after the tryptic 
digestion using streptavidin-conjugated beads before the MS analysis (38).  
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 Use of a cleavable cross-linking reagent such as PEAS (Scheme 4.1) is 
another way of making the MS analysis of cross-linked products easier (39, 40). The 
R group of PEAS indicated in Scheme 4.1 is transferred to Cys158 of Bcl-2Δ21 
through a disulfide-exchange reaction.  Upon photo activation, Bcl-2Δ21 is 
covalently linked to SERCA. Cleavage of the disulfide bond within the linker 
transfers the R group to SERCA. The MS data of the tryptic digests are analyzed for 
the peptide of SERCA modified with R and the MS/MS of this peptide would reflect 
the exact site of cross-linking.  
 
 
SCHEME 4.1: N-((2-pyridyldithio)ethyl)-4-azidosalicylamide (PEAS) 
(www.probes.com): The R group can be transferred to Cys158 of Bcl-2Δ21 through a 
disulfide-exchange reaction.  
 
 
In a preliminary photo cross-linking reaction using PEAS (following the same 
reaction steps as with BPM, mentioned in Chapter 2), bands that can be considered as 
cross-linked products of Bcl-2Δ21 were seen with the Bcl-2 antibody (data not 
shown). However the samples are not good enough for MS analysis, since smeared 
lanes are seen even with the Bcl-2Δ21/PEAS control sample and therefore the 
reaction conditions should be further optimized. Once the reaction conditions are 
R 
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optimized to observe clear cross-linked products in the western blots, the in-gel 
digests can be analyzed by MS. Since the MS data is searched for a single peptide of 
SERCA modified with R, not a cross-linked dipeptide as with BPM (see Chapter 2), 
the data analysis is relatively easier after cross-linking with PEAS. 
 
4.2.2: Effect of W188 of Bcl-2Δ21 on inactivation and translocation of SERCA. 
 W188 is another conserved residue located in the BH2 domain of Bcl-2. 
W188A mutation has been reported to completely diminish the anti apoptotic activity 
of human Bcl-2 (11, 12). Therefore W188A would be another important mutant of 
Bcl-2Δ21 on the inactivation and translocation of SERCA. The W188A mutant has 
already been generated in the lab using PCR-based site directed mutagenesis. 
As revealed by some preliminary experiments, the W188A mutant of Bcl-
2Δ21 can inactivate and also translocate SERCA from the Caveolae-Related Domains 
(CRD) of the SR membrane. The Ca2+-ATPase activity assay in the presence of 
W188A mutant shows a significant decrease in the enzymatic activity of SERCA (see 
Figure 4.1). When this mutant was used in an SDG fractionation experiment as 
explained in Chapter 3, SERCA is detected in almost all the fractions of the sucrose 
gradient compared to the control sample without Bcl-2Δ21 (compare (i) and (iii) of 
Figure 4.2). However since more degradation of SERCA is also seen with the same 
sample fractions containing W188A mutant, the inactivation and translocation of 
SERCA could be caused by some proteolytic enzymes co-purified during the 
purification of Bcl-2Δ21 (W188A). Therefore the results seen with this initial Ca2+-
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ATPase activity assay and SDG fractionation experiments are not very conclusive 
and the experiments should be repeated in the presence of more protease inhibitor.  
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FIGURE 4.1: Effect of W188A mutant of Bcl-2Δ21 on Ca2+-ATPase activity of 
SERCA: (●)-SR alone; (●)-SR mixed with wild type Bcl-2Δ21; (●)-SR mixed with 
W188A mutant of Bcl-2Δ21; 1-before incubation at 37 °C; 2-after 1h of    incubation 
at 37 °C. 
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FIGURE 4.2: Effect of W188A mutant of Bcl-2Δ21 on Sucrose Density Gradient 
(SDG) fractionation of SR: SDG fractions probed with SERCA antibody; (i) SR 
alone, (ii) SR incubated with WT, (iii) SR incubated with W188A. 
 
 
4.2.3: Other proteins involved in the interactions of SERCA/Bcl-2Δ21. 
As suggested by the GST-Bcl-2Δ21 binding assay, photo cross-linking and 
mass spectrometric data described in the Chapter 2, Mitsugumin-29 (Mg29) could be 
one of the other proteins involved in this SERCA-Bcl-2Δ21 interaction. Using 
1 2 3   4  5 6 7 8 
SR alone 
SR incubated with 
Bcl-2Δ21 (WT) 
SR incubated with 
Bcl-2Δ21 (W188A) 
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purified Mg29 in immunoprecipitation and GST-Bcl-2Δ21 binding assay experiments 
would confirm the association of Mg29 with the SERCA/Bcl-2Δ21 complex.  
Also since the  protective action of HSP70 (Heat Shock Protein 70) on 
inactivation of SERCA by Bcl-2Δ21  has already beenreported (29), cross-linking 
experiments involving HSP70/SERCA and HSP70/Bcl-2Δ21 would be helpful in 
elucidating the architecture of the protein complex thereby understanding the 
associated function of HSP70 in regulation of SERCA/Bcl-2Δ21 interactions.  
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Chapter 5:  
Unresolved Issues related to the SERCA/ Bcl-2Δ21 Investigation. 
In the Scientific Method of experimental investigations, an experiment should 
be reported with all the relevant observations. The relevant observations include not 
only the things noticed in a successful experiment but also the problems encountered. 
All the problems encountered throughout the course of the project are summarized 
here.  
 
5.1: Derivatization of Cys158 of Bcl-2Δ21 using Benzophenone-4-
maleimide (BPM). 
 The very first problem encountered was the difficulty in BPM labeling of the 
Cys158 of the wild type Bcl-2Δ21 for photo cross-linking experiments. Since the 
Cys158 is buried in the interior of the molecule, BPM derivatization under the native 
conditions was not successful and hence more time was spent figuring out the 
optimum denaturing conditions for the BPM labeling reaction. The successful 
removal of the denaturing agent from the medium before the cross-linking reaction, 
so that there is no effect from excess denaturing agent on the association of 
SERCA/Bcl-2Δ21, was also challenging. 
 In order to verify the presence of BPM labeled Bcl-2Δ21, ESI-IonTrap-MS 
was utilized at the first place after the in-gel tryptic digestion. However the peptide of 
Bcl-2Δ21 with BPM-Cys158 could not be found in the MS data even after repeated 
trials using different enzymatic digestion conditions (such as in-solution digestion, 
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different ratios of trypsin: Bcl-2Δ21, digestion in the presence of Ca2+ which is a co-
factor for trypsin) and also using a longer time for on-line chromatographic separation 
of tryptic peptides. Finally the BPM labeling of the Cys158 could be confirmed using 
ESI-FTICR-MS. 
 
5.2: Photo and chemical cross-linking reactions. 
 More time than expected was spent in optimizing cross-linking reaction 
conditions. The photo cross-linking experiment was repeated again and again, 
changing one variable at a time, until the optimum time for co-incubation of 
SERCA/Bcl-2Δ21 prior to the UV irradiation, the ratio of SERCA: Bcl-2Δ21, the UV 
irradiation time and also the UV intensity were established. The failure to confirm the 
photo cross-linked products in the western blot with SERCA antibody was another 
problem.  
The purified Sarcoplasmic Reticulum (SR) membrane, the source of SERCA, 
contains a number of other proteins with apparent molecular weights identical to 
SERCA, Bcl-2Δ21 and also to the size of cross-linked products. This was a major 
problem in cross-linking experiments which caused some ambiguity in the 
identification of cross-linked products of SERCA/Bcl-2Δ21 in the western blots. For 
the same reason the Coomassie Blue stained gels of cross-linked samples did not help 
at all in identification of the cross-linked bands and identical bands were seen even 
with the control sample without Bcl-2Δ21. However the presence of the SR 
membrane assures the native conformation of the trans-membrane protein, SERCA. If 
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SERCA were separated from the SR membrane, it should be incorporated into a 
synthetic membrane prior to each experiment and that would make the cross-linking 
experiment lengthier and more complex.  
Chemical cross-linking experiments, using amine and thiol reactive 
heterobifunctional chemical cross-linking reagents (Chapter 2), also caused some 
problems. Bcl-2Δ21 modified with the linker first, followed by the addition of SR, 
did not show any cross-linked products of Bcl-2Δ21. Possibly the modification of the 
amine groups of Bcl-2Δ21 by the linker prevents the association with SERCA. 
However when the reaction was performed starting with SR; i.e., the linker is added 
to SR first followed by the addition of Bcl-2Δ21, resulted in the cross-linked bands 
(see Chapter 2).  
 
5.3: Mass spectrometric analysis of cross-linked products. 
As mentioned earlier, since the purified Sarcoplasmic Reticulum (SR) 
membrane, the source of SERCA, contains number of other proteins, the cross-linked 
samples are always contaminated with these other unnecessary proteins. Therefore, 
relatively more efficient in-solution enzymatic digestion could not be involved and 
in-gel digestion which causes an extensive sample loss in each step was utilized. Even 
though the 1D-SDS-PAGE helped to some extent in separation of the cross-linked 
products from other SR proteins, the gel bands of interest were still contaminated 
with other proteins which are identical to the size of the cross-linked products. These 
other proteins are relatively highly abundant in the gel band and suppress the low 
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abundant cross-linked peptides during the MS run. The presence of these other 
proteins in the digest made the identification of the cross-linked peptides within the 
MS data more difficult.    
Even though there are several software tools are developed to date for protein 
cross-linking studies, one that identifies peptides cross-linked through the photo 
cross-linking reagent, BPM was not available at least by the time of the MS data 
analysis of the cross-linked samples.  Therefore the MS data were analyzed manually 
looking for the cross-linked peptides of SERCA and Bcl-2Δ21. This tedious, time 
consuming manual search was a major difficulty in the project.  
 
5.4: Mutants of Bcl-2Δ21. 
Due to the difficulty in BPM labeling of the Cys158 of the wild type Bcl-
2Δ21, for photo cross-linking experiments, the two double-cysteine mutants, S117C 
and S205C, of Bcl-2Δ21 were generated. However these mutants did not result in 
successful photo cross-linking reactions. Probably the presence of two Cys residues 
(Cys158 and Cys117/Cys 205) in the molecule caused some unfavorable homo 
oligomerization of Bcl-2Δ21 molecules. Therefore production of four single-cysteine 
mutants (S24C/C158S, S205C/C158S, S117C/C158S and S167C/C158S) was 
attempted. Only two mutations were successful (S24C/C158S and S205C/C158S) and 
the other two failed (S117C/C158S and S167C/C158S).  Expression of four other 
mutants (G145E, W188A, I14G and I 19G), which have been identified as loss-of-
function mutants on anti-apoptotic activity of Bcl-2Δ21, was attempted hoping to 
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study their effect on the SERCA/Bcl-2Δ21 interactions. However, only two 
mutagenesis reactions (G145E, W188A) were successful.  
The other difficulty associated with the mutants was the purification of 
enough proteins for experiments. Both the Cys-mutants, S24C/C158S and 
S205C/C158S, and also W188A of Bcl-2Δ21 yielded a very small amount of proteins 
from 1L of Luria-Bertani (LB) medium, compared to the wild type protein. 
Therefore, to have sufficient proteins for each experiment, each of these mutants was 
purified from bacteria grown in at least 2-3L of LB medium.  
 
  
 
 
 
